Mold Infections in Solid Organ Transplant Recipients

  • Patricia Muñoz
  • Maddalena Giannella
  • Antonio Vena
  • Emilio Bouza
Chapter

Abstract

Invasive mold infections represent an important cause of morbidity and mortality in solid organ transplant recipients. The advances in surgical techniques, immunosuppression, and prophylactic strategies have greatly modified the epidemiology of these infections in the transplant population with a progressive increase in infection caused by Aspergillus spp. and other less-common mold fungi, such as Zygomycetes, Scedosporium, and Fusarium spp. Herein, we summarize the recent changes in epidemiology of the most frequent mold infection affecting solid organ transplant patients, incorporating the newer data regarding specific risk factors, diagnostic strategy, and clinical and imaging findings. We also tried to give an overview of the current prophylaxis, treatments, and outcomes of these infections in solid organ transplant population.

Keywords

Fungal infections Mold infections Solid organ transplants Aspergillus spp. Mucorales 

References

  1. 1.
    Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev. 2005;18:44–69.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Gabardi S, Kubiak DW, Chandraker AK, Tullius SG. Invasive fungal infections and antifungal therapies in solid organ transplant recipients. Transpl Int. 2007;20:993–1015.PubMedCrossRefGoogle Scholar
  3. 3.
    Denning DW, Evans EG, Kibbler CC, et al. Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. British Society for Medical Mycology. Eur J Clin Microbiol Infect Dis. 1997;16:424–36.PubMedCrossRefGoogle Scholar
  4. 4.
    Marik PE. Fungal infections in solid organ transplantation. Expert Opin Pharmacother. 2006;7:297–305.PubMedCrossRefGoogle Scholar
  5. 5.
    Abbott KC, Hypolite I, Poropatich RK, et al. Hospitalizations for fungal infections after renal transplantation in the United States. Transpl Infect Dis. 2001;3:203–11.PubMedCrossRefGoogle Scholar
  6. 6.
    Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis. 2001;33:1692–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am. 2003;17:113–34. viii.PubMedCrossRefGoogle Scholar
  8. 8.
    Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-aspergillus mycelial fungi. Clin Infect Dis. 2003;37:221–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients: a prospective, multicenter, matched case-controlled study to assess risks and outcome. J Infect Dis. 2009;200:1002–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Hofflin JM, Potasman I, Baldwin JC, Oyer PE, Stinson EB, Remington JS. Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann Intern Med. 1987;106:209–16.PubMedCrossRefGoogle Scholar
  11. 11.
    Emery RW, Cork R, Christensen R, et al. Cardiac transplant patient at one year. Cyclosporine vs conventional immunosuppression. Chest. 1986;90:29–33.PubMedCrossRefGoogle Scholar
  12. 12.
    Loire R, Tabib A, Bastien O. [Fatal aspergillosis after cardiac transplantation. About 26 cases]. Ann Pathol. 1993;13:157–63.PubMedGoogle Scholar
  13. 13.
    Konduracka E. Opportunistic fungal infections in patients treated with heart transplantation—own centre experiences. Ann Transplant. 1998;3:21–4.PubMedGoogle Scholar
  14. 14.
    Bernabeu-Wittel M, Canas Garcia-Otero E, Herrero Romero M, et al. [Infectious complications of heart transplantation. A prospective study for the first 6 years of a transplantation program]. Rev Clin Esp. 1999;199:489–95.PubMedGoogle Scholar
  15. 15.
    Grossi P, De Maria R, Caroli A, Zaina MS, Minoli L. Infections in heart transplant recipients: the experience of the Italian Heart Transplantation Program. Italian Study Group on Infections in Heart Transplantation. J Heart Lung Transplant. 1992;11:847–66.PubMedGoogle Scholar
  16. 16.
    Schowengerdt KO, Naftel DC, Seib PM, et al. Infection after pediatric heart transplantation: results of a multiinstitutional study. The Pediatric Heart Transplant Study Group. J Heart Lung Transplant. 1997;16:1207–16.PubMedGoogle Scholar
  17. 17.
    Miller LW, Naftel DC, Bourge RC, et al. Infection after heart transplantation: a multiinstitutional study. Cardiac Transplant Research Database Group. J Heart Lung Transplant. 1994;13:381–92. discussion 393.PubMedGoogle Scholar
  18. 18.
    Menafoglio A, Cometta A, Berguer DG, et al. [Infectious complications in cardiac transplantation: Lausanne experience]. Schweiz Med Wochenschr. 1994;124:1479–88.Google Scholar
  19. 19.
    Cisneros JM, Munoz P, Torre-Cisneros J, et al. Pneumonia after heart transplantation: a multi-institutional study. Spanish Transplantation Infection Study Group. Clin Infect Dis. 1998;27:324–31.PubMedCrossRefGoogle Scholar
  20. 20.
    Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis. 2001;33:629–40.PubMedCrossRefGoogle Scholar
  21. 21.
    Munoz P, Ceron I, Valerio M, et al. Invasive aspergillosis among heart transplant recipients: a 24-year perspective. J Heart Lung Transplant. 2014;33:278–88.PubMedCrossRefGoogle Scholar
  22. 22.
    Munoz P, Valerio M, Palomo J, et al. Targeted antifungal prophylaxis in heart transplant recipients. Transplantation. 2013;96:664–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Tissot F, Pascual M, Hullin R, et al. Impact of targeted antifungal prophylaxis in heart transplant recipients at high risk for early invasive fungal infection. Transplantation. 2014;97:1192–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Husain S, Kwak EJ, Obman A, et al. Prospective assessment of platelia aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant. 2004;4:796–802.PubMedCrossRefGoogle Scholar
  25. 25.
    Koo S, Kubiak DW, Issa NC, et al. A targeted peritransplant antifungal strategy for the prevention of invasive fungal disease after lung transplantation: a sequential cohort analysis. Transplantation. 2012;94:281–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Kusne S, Dummer JS, Singh N, et al. Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore). 1988;67:132–43.CrossRefGoogle Scholar
  27. 27.
    Wajszczuk CP, Dummer JS, Ho M, et al. Fungal infections in liver transplant recipients. Transplantation. 1985;40:347–53.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Castaldo P, Stratta RJ, Wood RP, et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg. 1991;126:149–56.PubMedCrossRefGoogle Scholar
  29. 29.
    Hadley S, Samore MH, Lewis WD, Jenkins RL, Karchmer AW, Hammer SM. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or fk506 as primary immunosuppression. Transplantation. 1995;59:851–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Rabkin JM, Oroloff SL, Corless CL, et al. Association of fungal infection and increased mortality in liver transplant recipients. Am J Surg. 2000;179:426–30.PubMedCrossRefGoogle Scholar
  31. 31.
    Singh N, Wagener MM, Marino IR, Gayowski T. Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation. 2002;73:63–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Fung JJ. Fungal infection in liver transplantation. Transpl Infect Dis. 2002;4:18–23.PubMedCrossRefGoogle Scholar
  33. 33.
    Gavalda J, Len O, San Juan R, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case–control study. Clin Infect Dis. 2005;41:52–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol. 2005;43 Suppl 1:S49–58.PubMedCrossRefGoogle Scholar
  35. 35.
    Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50:1101–11.PubMedCrossRefGoogle Scholar
  36. 36.
    Guillemain R, Lavarde V, Amrein C, Chevalier P, Guinvarc’h A, Glotz D. [Aspergillosis and renal, heart and lung transplantation]. Pathol Biol (Paris). 1994;42:661–9.Google Scholar
  37. 37.
    Singh N. Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design. Clin Infect Dis. 2004;39 Suppl 4:S200–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Lumbreras C, Fernandez I, Velosa J, Munn S, Sterioff S, Paya CV. Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome. Clin Infect Dis. 1995;20:514–20.PubMedCrossRefGoogle Scholar
  39. 39.
    Rubin RH, Wolfson JS, Cosimi AB, Tolkoff Rubin NE. Infection in the renal transplant recipient. Am J Med. 1981;70:405–11.PubMedCrossRefGoogle Scholar
  40. 40.
    Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338:1741–51.PubMedCrossRefGoogle Scholar
  41. 41.
    Rubin RH, Schaffner A, Speich R. Introduction to the Immunocompromised Host Society consensus conference on epidemiology, prevention, diagnosis, and management of infections in solid-organ transplant patients. Clin Infect Dis. 2001;33 Suppl 1:S1–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Kusne S, Torre-Cisneros J, Manez R, et al. Factors associated with invasive lung aspergillosis and the significance of positive aspergillus culture after liver transplantation. J Infect Dis. 1992;166:1379–83.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis. 1994;170:644–52.PubMedCrossRefGoogle Scholar
  44. 44.
    Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis. 2003;36:46–52.PubMedCrossRefGoogle Scholar
  45. 45.
    Husain S, Munoz P, Forrest G, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis. 2005;40:89–99.PubMedCrossRefGoogle Scholar
  46. 46.
    Fishman JA. Overview: fungal infections in the transplant patient. Transpl Infect Dis. 2002;4:3–11.PubMedCrossRefGoogle Scholar
  47. 47.
    Selby R, Ramirez CB, Singh R, et al. Brain abscess in solid organ transplant recipients receiving cyclosporine-based immunosuppression. Arch Surg. 1997;132:304–10.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Rubin RH. Overview: pathogenesis of fungal infection in the organ transplant recipient. Transpl Infect Dis. 2002;4:12–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Lortholary O, Charlier C, Lebeaux D, Lecuit M, Consigny PH. Fungal infections in immunocompromised travelers. Clin Infect Dis. 2013;56:861–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Singh N, Chang FY, Gayowski T, Marino IR. Infections due to dematiaceous fungi in organ transplant recipients: case report and review. Clin Infect Dis. 1997;24:369–74.PubMedCrossRefGoogle Scholar
  51. 51.
    Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96:333–60.PubMedCrossRefGoogle Scholar
  52. 52.
    Kubak BM. Fungal infection in lung transplantation. Transpl Infect Dis. 2002;4:24–31.PubMedCrossRefGoogle Scholar
  53. 53.
    Briegel J, Forst H, Spill B, et al. Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis. 1995;14:375–82.PubMedCrossRefGoogle Scholar
  54. 54.
    Nieto-Rodriguez JA, Kusne S, Manez R, et al. Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann Surg. 1996;223:70–6.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Patel R, Portela D, Badley AD, et al. Risk factors of invasive candida and non-candida fungal infections after liver transplantation. Transplantation. 1996;62:926–34.PubMedCrossRefGoogle Scholar
  56. 56.
    Singh N, Gayowski T, Wagener MM, Doyle H, Marino IR. Invasive fungal infections in liver transplant recipients receiving tacrolimus as the primary immunosuppressive agent. Clin Infect Dis. 1997;24:179–84.PubMedCrossRefGoogle Scholar
  57. 57.
    Gayowski T, Marino IR, Singh N, et al. Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation. 1998;65:499–504.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Nuno J, Cuervas-Mons V, Vicente E, et al. Prolonged graft cold ischemia: a risk factor for early bacterial and fungal infection in liver transplant recipients. Transplant Proc. 1995;27:2323–5.PubMedGoogle Scholar
  59. 59.
    Singh N, Arnow PM, Bonham A, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation. 1997;64:716–20.PubMedCrossRefGoogle Scholar
  60. 60.
    Garcia S, Roque J, Ruza F, et al. Infection and associated risk factors in the immediate postoperative period of pediatric liver transplantation: a study of 176 transplants. Clin Transplant. 1998;12:190–7.PubMedGoogle Scholar
  61. 61.
    Kibbler CC. Infections in liver transplantation: risk factors and strategies for prevention. J Hosp Infect. 1995;30:209–17.PubMedCrossRefGoogle Scholar
  62. 62.
    Snydman DR. Epidemiology of infections after solid-organ transplantation. Clin Infect Dis. 2001;33:S5–8.PubMedCrossRefGoogle Scholar
  63. 63.
    George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, Medimmune, Inc. Gaithersburg, Maryland. Am J Med. 1997;103:106–13.PubMedCrossRefGoogle Scholar
  64. 64.
    Gotzinger P, Sautner T, Wamser P, et al. [Early postoperative infections after liver transplantation—pathogen spectrum and risk factors]. Wien Klin Wochenschr. 1996;108:795–801.PubMedGoogle Scholar
  65. 65.
    Tollemar J, Ericzon BG, Barkholt L, Andersson J, Ringden O, Groth CG. Risk factors for deep Candida infections in liver transplant recipients. Transplant Proc. 1990;22:1826–7.PubMedGoogle Scholar
  66. 66.
    Aldebert D, Pinel C, Brion JP, Ambroise-Thomas P, Grillot R. [Role of local immunity in invasive pulmonary aspergillosis]. Presse Med. 2001;30:1258–64.PubMedGoogle Scholar
  67. 67.
    Munoz P, Rodriguez C, Bouza E, et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant. 2004;4:636–43.PubMedCrossRefGoogle Scholar
  68. 68.
    Gavalda J, Meije Y, Fortun J, et al. Invasive fungal infections in solid organ transplant recipients. Clin Microbiol Infect. 2014;20 Suppl 7:27–48.PubMedCrossRefGoogle Scholar
  69. 69.
    Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358–66.PubMedCrossRefGoogle Scholar
  70. 70.
    Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis. 1993;16:677–88.PubMedCrossRefGoogle Scholar
  71. 71.
    Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin b lipid complex in lung transplant recipients. Transplantation. 2001;72:545–8.PubMedCrossRefGoogle Scholar
  72. 72.
    McAdams HP, Erasmus JJ, Palmer SM. Complications (excluding hyperinflation) involving the native lung after single-lung transplantation: incidence, radiologic features, and clinical importance. Radiology. 2001;218:233–41.PubMedCrossRefGoogle Scholar
  73. 73.
    Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant. 2006;6:3008–16.PubMedCrossRefGoogle Scholar
  74. 74.
    Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998;26:781–803. quiz 804–785.PubMedCrossRefGoogle Scholar
  75. 75.
    Fortun J, Martin-Davila P, Moreno S, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl. 2002;8:1065–70.PubMedCrossRefGoogle Scholar
  76. 76.
    Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore). 1999;78:123–38.CrossRefGoogle Scholar
  77. 77.
    Eschenauer GA, Kwak EJ, Humar A, et al. Targeted versus universal antifungal prophylaxis among liver transplant recipients. Am J Transplant. 2015;15:180–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis. 2006;43:577–84.PubMedCrossRefGoogle Scholar
  79. 79.
    Westney GE, Kesten S, De Hoyos A, Chapparro C, Winton T, Maurer JR. Aspergillus infection in single and double lung transplant recipients. Transplantation. 1996;61:915–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Yeldandi V, Laghi F, McCabe MA, et al. Aspergillus and lung transplantation. J Heart Lung Transplant. 1995;14:883–90.PubMedGoogle Scholar
  81. 81.
    Guillemain R, Lavarde V, Amrein C, Chevalier P, Guinvarc’h A, Glotz D. Invasive aspergillosis after transplantation. Transplant Proc. 1995;27:1307–9.PubMedGoogle Scholar
  82. 82.
    Muñoz P, Torre-Cisneros J, Bouza E, et al. A large multicentric study: invasive aspergillosis in transplant recipients. In: 36th Conference on Antimicrobial Agents and Chemotherapy; New Orleans. Washington, DC: American Society for Microbiology; 1996.Google Scholar
  83. 83.
    Brown Jr RS, Lake JR, Katzman BA, et al. Incidence and significance of aspergillus cultures following liver and kidney transplantation. Transplantation. 1996;61:666–9.PubMedCrossRefGoogle Scholar
  84. 84.
    Torre-Cisneros J, Manez R, Kusne S, Alessiani M, Martin M, Starzl TE. The spectrum of aspergillosis in liver transplant patients: comparison of fk 506 and cyclosporine immunosuppression. Transplant Proc. 1991;23:3040–1.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Weiland D, Ferguson RM, Peterson PK, Snover DC, Simmons RL, Najarian JS. Aspergillosis in 25 renal transplant patients. Epidemiology, clinical presentation, diagnosis, and management. Ann Surg. 1983;198:622–9.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Singh N. Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis. 2000;31:545–53.PubMedCrossRefGoogle Scholar
  87. 87.
    Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis. 1999;1:229–36.PubMedCrossRefGoogle Scholar
  88. 88.
    Munoz P, Burillo A, Bouza E. Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit. Int J Antimicrob Agents. 2000;15:83–90.PubMedCrossRefGoogle Scholar
  89. 89.
    Munoz P, Palomo J, Guembe P, Rodriguez-Creixems M, Gijon P, Bouza E. Lung nodular lesions in heart transplant recipients. J Heart Lung Transplant. 2000;19:660–7.PubMedCrossRefGoogle Scholar
  90. 90.
    Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev. 1997;10:86–124.PubMedPubMedCentralGoogle Scholar
  91. 91.
    Hibberd PL, Rubin RH. Clinical aspects of fungal infection in organ transplant recipients. Clin Infect Dis. 1994;19:S33–40.PubMedCrossRefGoogle Scholar
  92. 92.
    Grossi P, Farina C, Fiocchi R, Dalla Gasperina D. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation. 2000;70:112–6.PubMedGoogle Scholar
  93. 93.
    Hummel M, Thalmann U, Jautzke G, Staib F, Seibold M, Hetzer R. Fungal infections following heart transplantation. Mycoses. 1992;35:23–34.PubMedCrossRefGoogle Scholar
  94. 94.
    Montoya JG, Chaparro SV, Celis D, et al. Invasive aspergillosis in the setting of cardiac transplantation. Clin Infect Dis. 2003;37 Suppl 3:S281–92.PubMedCrossRefGoogle Scholar
  95. 95.
    Cahill BC, Hibbs JR, Savik K, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest. 1997;112:1160–4.PubMedCrossRefGoogle Scholar
  96. 96.
    Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine (Baltimore). 1996;75:142–56.CrossRefGoogle Scholar
  97. 97.
    Mehrad B, Paciocco G, Martinez FJ, Ojo TC, Iannettoni MD, Lynch 3rd JP. Spectrum of aspergillus infection in lung transplant recipients: case series and review of the literature. Chest. 2001;119:169–75.PubMedCrossRefGoogle Scholar
  98. 98.
    Birsan T, Taghavi S, Klepetko W. Treatment of aspergillus-related ulcerative tracheobronchitis in lung transplant recipients. J Heart Lung Transplant. 1998;17:437–8.PubMedGoogle Scholar
  99. 99.
    Brenier-Pinchart MP, Lebeau B, Devouassoux G, et al. Aspergillus and lung transplant recipients: a mycologic and molecular epidemiologic study. J Heart Lung Transplant. 1998;17:972–9.PubMedGoogle Scholar
  100. 100.
    Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant. 2003;22:258–66.PubMedCrossRefGoogle Scholar
  101. 101.
    Kiuchi T, Tanaka K. [Invasive mycosis in liver transplantation]. Nippon Ishinkin Gakkai Zasshi. 2001;42:189–93.CrossRefGoogle Scholar
  102. 102.
    Neofytos D, Fishman JA, Horn D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis. 2010;12:220–9.PubMedCrossRefGoogle Scholar
  103. 103.
    Denning DW. Report on a European Science Foundation workshop on invasive aspergillosis. www.aspergillus.man.ac.uk. 1998.
  104. 104.
    Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 1996;23:608–15.PubMedCrossRefGoogle Scholar
  105. 105.
    Chowdhary A, Meis JF, Guarro J, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect. 2014;20 Suppl 3:47–75.PubMedCrossRefGoogle Scholar
  106. 106.
    Singh N, Husain S. Aspergillosis in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:228–41.PubMedCrossRefGoogle Scholar
  107. 107.
    De Vuyst D, Surmont I, Verhaegen J, Vanhaecke J. Tibial osteomyelitis due to Aspergillus flavus in a heart transplant patient. Infection. 1992;20:48–9.PubMedCrossRefGoogle Scholar
  108. 108.
    Carter JM, Green WR, Callender CO, Peters B. Pulmonary cavitation with nocardia and aspergillus in a renal transplant patient. J Natl Med Assoc. 1990;82:527–31.PubMedPubMedCentralGoogle Scholar
  109. 109.
    Monteforte JS, Wood CA. Pneumonia caused by nocardia nova and Aspergillus fumigatus after cardiac transplantation. Eur J Clin Microbiol Infect Dis. 1993;12:112–4.PubMedCrossRefGoogle Scholar
  110. 110.
    Fakih MG, Barden GE, Oakes CA, Berenson CS. First reported case of Aspergillus granulosus infection in a cardiac transplant patient. J Clin Microbiol. 1995;33:471–3.PubMedPubMedCentralGoogle Scholar
  111. 111.
    Vermeulen E, Maertens J, De Bel A, et al. Nationwide surveillance of azole resistance in aspergillus diseases. Antimicrob Agents Chemother. 2015;59:4569–76.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    van der Linden JW, Arendrup MC, Warris A, et al. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis. 2015;21:1041–4.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Fuhren J, Voskuil WS, Boel CH, et al. High prevalence of azole resistance in Aspergillus fumigatus isolates from high-risk patients. J Antimicrob Chemother. 2015;70:2894–8.PubMedCrossRefGoogle Scholar
  114. 114.
    Choukri F, Botterel F, Sitterle E, et al. Prospective evaluation of azole resistance in Aspergillus fumigatus clinical isolates in France. Med Mycol. 2015;53:593–6.PubMedCrossRefGoogle Scholar
  115. 115.
    Blanco JL, Hontecillas R, Bouza E, et al. Correlation between the elastase activity index and invasiveness of clinical isolates of Aspergillus fumigatus. J Clin Microbiol. 2002;40:1811–3.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Pelaez T, Munoz P, Guinea J, et al. Outbreak of invasive aspergillosis after major heart surgery caused by spores in the air of the intensive care unit. Clin Infect Dis. 2012;54:e24–31.PubMedCrossRefGoogle Scholar
  117. 117.
    Sughayer M, DeGirolami PC, Khettry U, et al. Human infection caused by Exophiala pisciphila: case report and review. Rev Infect Dis. 1991;13:379–82.PubMedCrossRefGoogle Scholar
  118. 118.
    Boelaert JDJ, DeVos A, Coninx S. [Cutaneous aspergillosis in a case of renal transplantation]. Arch Belg Dermatol Syphiligr. 1970;26:561–5.Google Scholar
  119. 119.
    Stiller MJ, Teperman L, Rosenthal SA, et al. Primary cutaneous infection by aspergillus ustus in a 62-year-old liver transplant recipient. J Am Acad Dermatol. 1994;31:344–7.PubMedCrossRefGoogle Scholar
  120. 120.
    van Burik JA, Colven R, Spach DH. Cutaneous aspergillosis. J Clin Microbiol. 1998;36:3115–21.PubMedPubMedCentralGoogle Scholar
  121. 121.
    Kim SH, Ha YE, Youn JC, et al. Fatal scedosporiosis in multiple solid organ allografts transmitted from a nearly-drowned donor. Am J Transplant. 2015;15:833–40.PubMedCrossRefGoogle Scholar
  122. 122.
    Kaul DR, Covington S, Taranto S, et al. Solid organ transplant donors with central nervous system infection. Transplantation. 2014;98:666–70.PubMedCrossRefGoogle Scholar
  123. 123.
    Gomez CA, Singh N. Donor-derived filamentous fungal infections in solid organ transplant recipients. Curr Opin Infect Dis. 2013;26:309–16.PubMedCrossRefGoogle Scholar
  124. 124.
    Cenci E, Mencacci A, Del Sero G, et al. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis. 1999;180:1957–68.PubMedCrossRefGoogle Scholar
  125. 125.
    Roilides E, Dimitriadou-Georgiadou A, Sein T, Kadiltsoglou I, Walsh TJ. Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus. Infect Immun. 1998;66:5999–6003.PubMedPubMedCentralGoogle Scholar
  126. 126.
    Jolink H, Meijssen IC, Hagedoorn RS, et al. Characterization of the t-cell-mediated immune response against the Aspergillus fumigatus proteins crf1 and catalase 1 in healthy individuals. J Infect Dis. 2013;208:847–56.PubMedCrossRefGoogle Scholar
  127. 127.
    Weimer R, Melk A, Daniel V, Friemann S, Padberg W, Opelz G. Switch from cyclosporine a to tacrolimus in renal transplant recipients: impact on th1, th2, and monokine responses. Hum Immunol. 2000;61:884–97.PubMedCrossRefGoogle Scholar
  128. 128.
    Netea MG, Warris A, Van der Meer JW, et al. Aspergillus fumigatus evades immune recognition during germination through loss of toll-like receptor-4-mediated signal transduction. J Infect Dis. 2003;188:320–6.PubMedCrossRefGoogle Scholar
  129. 129.
    Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med. 2008;359:1766–77.PubMedPubMedCentralCrossRefGoogle Scholar
  130. 130.
    Wojtowicz A, Lecompte TD, Bibert S, et al. Ptx3 polymorphisms and invasive mold infections after solid organ transplant. Clin Infect Dis. 2015;61:619–22.PubMedCrossRefGoogle Scholar
  131. 131.
    Ankersmit HJ, Deicher R, Moser B, et al. Impaired T cell proliferation, increased soluble death-inducing receptors and activation-induced T cell death in patients undergoing haemodialysis. Clin Exp Immunol. 2001;125:142–8.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Munoz P, Vena A, Ceron I, et al. Invasive pulmonary aspergillosis in heart transplant recipients: two radiologic patterns with a different prognosis. J Heart Lung Transplant. 2014;33:1034–40.PubMedCrossRefGoogle Scholar
  133. 133.
    Faggian G, Livi U, Bortolotti U, et al. Itraconazole therapy for acute invasive pulmonary aspergillosis in heart transplantation. Transplant Proc. 1989;21:2506–7.PubMedGoogle Scholar
  134. 134.
    Hummel M, Schuler S, Weber U, et al. Aspergillosis with aspergillus osteomyelitis and diskitis after heart transplantation: surgical and medical management. J Heart Lung Transplant. 1993;12:599–603.PubMedGoogle Scholar
  135. 135.
    Keane WM, Potsic WP, Perloff LJ, Barker CF, Grossman RA. Aspergillus thyroiditis. Otolaryngology. 1978;86:ORL-761–5.Google Scholar
  136. 136.
    Kinder RB, Jourdan MH. Disseminated aspergillosis and bleeding colonic ulcers in renal transplant patient. J R Soc Med. 1985;78:338–9.PubMedPubMedCentralCrossRefGoogle Scholar
  137. 137.
    Murray HW, Moore JO, Luff RD. Disseminated aspergillosis in a renal transplant patient: diagnostic difficulties re-emphasized. Johns Hopkins Med J. 1975;137:235–7.PubMedGoogle Scholar
  138. 138.
    Solary E, Rifle G, Chalopin JM, et al. Disseminated aspergillosis revealed by thyroiditis in a renal allograft recipient. Transplantation. 1987;44:839–40.PubMedCrossRefGoogle Scholar
  139. 139.
    Simon DM, Levin S. Infectious complications of solid organ transplantations. Infect Dis Clin North Am. 2001;15:521–49.PubMedCrossRefGoogle Scholar
  140. 140.
    Torre-Cisneros J, Lopez OL, Kusne S, et al. CNS aspergillosis in organ transplantation: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1993;56:188–93.PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Kourkoumpetis TK, Desalermos A, Muhammed M, Mylonakis E. Central nervous system aspergillosis: a series of 14 cases from a general hospital and review of 123 cases from the literature. Medicine (Baltimore). 2012;91:328–36.CrossRefGoogle Scholar
  142. 142.
    Bonham CA, Dominguez EA, Fukui MB, et al. Central nervous system lesions in liver transplant recipients: prospective assessment of indications for biopsy and implications for management. Transplantation. 1998;66:1596–604.PubMedCrossRefGoogle Scholar
  143. 143.
    Paterson DL, Dominguez EA, Chang FY, Snydman DR, Singh N. Infective endocarditis in solid organ transplant recipients. Clin Infect Dis. 1998;26:689–94.PubMedCrossRefGoogle Scholar
  144. 144.
    Loria KM, Salinger MH, Frohlich TG, Gendelman MD, Cook FV, Arentzen CE. Primary cutaneous aspergillosis in a heart transplant recipient treated with surgical excision and oral itraconazole. J Heart Lung Transplant. 1992;11:156–9.PubMedGoogle Scholar
  145. 145.
    Greenbaum RS, Roth JS, Grossman ME. Subcutaneous nodule in a cardiac transplant. Cutaneous aspergillosis. Arch Dermatol. 1993;129:1191, 1194.Google Scholar
  146. 146.
    Eworo A, Munoz P, Yanez JF, et al. [Cardiac invasive aspergillosis in a heart transplant recipient]. Rev Iberoam Micol. 2011;28:134–8.PubMedCrossRefGoogle Scholar
  147. 147.
    Kramer MR, Denning DW, Marshall SE, et al. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis. 1991;144:552–6.PubMedCrossRefGoogle Scholar
  148. 148.
    Pla MP, Berenguer J, Arzuaga JA, Banares R, Polo JR, Bouza E. Surgical wound infection by Aspergillus fumigatus in liver transplant recipients. Diagn Microbiol Infect Dis. 1992;15:703–6.PubMedCrossRefGoogle Scholar
  149. 149.
    Durand F, Bernuau J, Dupont B, et al. Aspergillus intraabdominal abscess after liver transplantation successfully treated with itraconazole. Transplantation. 1992;54:734–5.PubMedCrossRefGoogle Scholar
  150. 150.
    Ioannidis JP, Snydman DR, Rohrer RJ, Freeman RB, Haug CE. Aspergillus fumigatus infection of a biloma. Clin Infect Dis. 1995;20:1427–8.PubMedCrossRefGoogle Scholar
  151. 151.
    Lorf T, Braun F, Ruchel R, Muller A, Sattler B, Ringe B. Systemic mycoses during prophylactical use of liposomal amphotericin b (ambisome) after liver transplantation. Mycoses. 1999;42:47–53.PubMedCrossRefGoogle Scholar
  152. 152.
    Woods GL, Wood RP, Shaw Jr BW. Aspergillus endocarditis in patients without prior cardiovascular surgery: report of a case in a liver transplant recipient and review. Rev Infect Dis. 1989;11:263–72.PubMedCrossRefGoogle Scholar
  153. 153.
    Hunt KE, Glasgow BJ. Aspergillus endophthalmitis. An unrecognized endemic disease in orthotopic liver transplantation. Ophthalmology. 1996;103:757–67.PubMedCrossRefGoogle Scholar
  154. 154.
    Papanicolaou GA, Meyers BR, Fuchs WS, et al. Infectious ocular complications in orthotopic liver transplant patients. Clin Infect Dis. 1997;24:1172–7.PubMedCrossRefGoogle Scholar
  155. 155.
    Pararajasegaram P, James T, Dabbs T, Davies M, Lodge P, Pollard S. Aspergillus endophthalmitis in orthotopic liver transplant. Ophthalmology. 1997;104:1061–2.PubMedCrossRefGoogle Scholar
  156. 156.
    Saliba F, Delvart V, Ichai P, et al. Fungal infections after liver transplantation: outcomes and risk factors revisited in the meld era. Clin Transplant. 2013;27:E454–61.PubMedCrossRefGoogle Scholar
  157. 157.
    Singh N, Heitman J. Antifungal attributes of immunosuppressive agents: new paradigms in management and elucidating the pathophysiologic basis of opportunistic mycoses in organ transplant recipients. Transplantation. 2004;77:795–800.PubMedCrossRefGoogle Scholar
  158. 158.
    Nampoory MR, Khan ZU, Johny KV, et al. Invasive fungal infections in renal transplant recipients. J Infect. 1996;33:95–101.PubMedCrossRefGoogle Scholar
  159. 159.
    de Castro Garcia FJ, Hernandez-Mezquita MA, Adeva Bartolome MT, Barrueco Ferrero M, Bondia A. [Pulmonary infiltrate in renal transplantation patient]. Rev Clin Esp. 2000;200:693–4.PubMedCrossRefGoogle Scholar
  160. 160.
    Sayiner A, Kursat S, Toz H, Duman S, Onal B, Tumbay E. Pseudomembranous necrotizing bronchial aspergillosis in a renal transplant recipient. Nephrol Dial Transplant. 1999;14:1784–5.PubMedCrossRefGoogle Scholar
  161. 161.
    Marks WH, Florence L, Lieberman J, et al. Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient. Transplantation. 1996;61:1771–4.PubMedCrossRefGoogle Scholar
  162. 162.
    Nazzari C, Brenciaglia M, Mancini C, Alfani D, Berloco P, Pretagostini R. [Pulmonary aspergillosis in patients having undergone a kidney transplant]. Clin Ter. 1987;121:197–200.PubMedGoogle Scholar
  163. 163.
    Pechan WB, Novick AC, Lalli A, Gephardt G. Pulmonary nodules in a renal transplant recipient. J Urol. 1980;124:111–4.PubMedGoogle Scholar
  164. 164.
    Briggs WA, Merrill JP, O’Brien TF, Wilson RE, Birtch AG, Murray JE. Severe pneumonia in renal transplant patients. One year’s experience. Ann Intern Med. 1971;75:887–94.PubMedCrossRefGoogle Scholar
  165. 165.
    Bach MC, Adler JL, Breman J, et al. Influence of rejection therapy on fungal and nocardial infections in renal-transplant recipients. Lancet. 1973;1:180–4.PubMedCrossRefGoogle Scholar
  166. 166.
    Gustafson TL, Schaffner W, Lavely GB, Stratton CW, Johnson HK, Hutcheson Jr RH. Invasive aspergillosis in renal transplant recipients: correlation with corticosteroid therapy. J Infect Dis. 1983;148:230–8.PubMedCrossRefGoogle Scholar
  167. 167.
    Langlois RP, Flegel KM, Meakins JL, Morehouse DD, Robson HG, Guttmann RD. Cutaneous aspergillosis with fatal dissemination in a renal transplant recipient. Can Med Assoc J. 1980;122:673–6.PubMedPubMedCentralGoogle Scholar
  168. 168.
    Kim SW, Nah MY, Yeum CH, et al. Pelvic aspergillosis with tubo-ovarian abscess in a renal transplant recipient. J Infect. 2001;42:215–7.PubMedCrossRefGoogle Scholar
  169. 169.
    Kaplan-Pavlovcic S, Masera A, Ovcak Z, Kmetec A. Prostatic aspergillosis in a renal transplant recipient. Nephrol Dial Transplant. 1999;14:1778–80.PubMedCrossRefGoogle Scholar
  170. 170.
    Singer AJ, Kubak B, Anders KH. Aspergillosis of the testis in a renal transplant recipient. Urology. 1998;51:119–21.PubMedCrossRefGoogle Scholar
  171. 171.
    Shirwany A, Sargent SJ, Dmochowski RR, Bronze MS. Urinary tract aspergillosis in a renal transplant recipient. Clin Infect Dis. 1998;27:1336.PubMedCrossRefGoogle Scholar
  172. 172.
    Hadaya K, Akposso K, Costa de Beauregard MA, Haymann JP, Rondeau E, Sraer JD. Isolated urinary aspergillosis in a renal transplant recipient. Nephrol Dial Transplant. 1998;13:2382–4.Google Scholar
  173. 173.
    Guleria S, Seth A, Dinda AK, et al. Ureteric aspergilloma as the cause of ureteric obstruction in a renal transplant recipient. Nephrol Dial Transplant. 1998;13:792–3.PubMedCrossRefGoogle Scholar
  174. 174.
    Maranes A, Portoles J, Blanco J, et al. Aspergillus infection of a renal allograft without evidence of a site of origin. Nephrol Dial Transplant. 1996;11:1639–42.PubMedCrossRefGoogle Scholar
  175. 175.
    Franco M, Van Elslande L, Robino C, et al. Aspergillus arthritis of the shoulder in a renal transplant recipient. Failure of itraconazole therapy. Rev Rhum Engl Ed. 1995;62:215–8.PubMedGoogle Scholar
  176. 176.
    Cassuto-Viguier E, Mondain JR, Van Elslande L, et al. Fatal outcome of Aspergillus fumigatus arthritis in a renal transplant recipient. Transplant Proc. 1995;27:2461.PubMedGoogle Scholar
  177. 177.
    Mrowka C, Heintz B, Weis J, Mayfrank L, Reul J, Sieberth HG. Isolated cerebral aspergilloma—long-term survival of a renal transplant recipient. Clin Nephrol. 1997;47:394–6.PubMedGoogle Scholar
  178. 178.
    Delmas Y, Merville P, Dousset V, Dervau-Durieux L, Morel D, Potaux L. A renal transplant recipient with acute paraparesis due to an aspergillus epidural abscess. Nephrol Dial Transplant. 1997;12:2185–7.PubMedCrossRefGoogle Scholar
  179. 179.
    Ingwer I, McLeish KR, Tight RR, White AC. Aspergillus fumigatus epidural abscess in a renal transplant recipient. Arch Intern Med. 1978;138:153–4.PubMedCrossRefGoogle Scholar
  180. 180.
    Viertel A, Ditting T, Pistorius K, Geiger H, Scheuermann EH, Just-Nubling G. An unusual case of aspergillus endocarditis in a kidney transplant recipient. Transplantation. 1999;68:1812–3.PubMedCrossRefGoogle Scholar
  181. 181.
    Marin P, Garcia-Martos P, Garcia-Doncel A, et al. Endocarditis by Aspergillus fumigatus in a renal transplant. Mycopathologia. 1999;145:127–9.PubMedCrossRefGoogle Scholar
  182. 182.
    Bibashi E, Papagianni A, Kelesidis A, Antoniadou R, Papadimitriou M. Peritonitis due to Aspergillus niger in a patient on continuous ambulatory peritoneal dialysis shortly after kidney graft rejection. Nephrol Dial Transplant. 1993;8:185–7.PubMedGoogle Scholar
  183. 183.
    Ardiles L, Pisano R, Mezzano S, Corti D. [External iliac artery rupture as a manifestation of aspergillosis in a renal transplant recipient]. Rev Med Chil. 1990;118:566–71.Google Scholar
  184. 184.
    Weiss JN, Hutchins RK, Balogh K. Simultaneous aspergillus endophthalmitis and cytomegalovirus retinitis after kidney transplantation. Retina. 1988;8:193–8.PubMedCrossRefGoogle Scholar
  185. 185.
    Tilney NL, Kohler TR, Strom TB. Cerebromeningitis in immunosuppressed recipients of renal allografts. Ann Surg. 1982;195:104–9.PubMedPubMedCentralCrossRefGoogle Scholar
  186. 186.
    Cheung TM, Simard D. Systemic aspergillus infection: report of a fatal case nine months after renal homograft transplantation. Br J Urol. 1971;43:174–6.PubMedCrossRefGoogle Scholar
  187. 187.
    Naidoff MA, Green WR. Endogenous aspergillus endophthalmitis occurring after kidney transplant. Am J Ophthalmol. 1975;79:502–9.PubMedCrossRefGoogle Scholar
  188. 188.
    Garrido J, Labrador PJ, Lerma L, et al. [Vascular aspergillus infection in two recipients of kidneys from the same donor]. Nefrologia. 2004;24(Suppl 3):30–34.Google Scholar
  189. 189.
    Patterson TF. Approaches to fungal diagnosis in transplantation. Transpl Infect Dis. 1999;1:262–72.PubMedCrossRefGoogle Scholar
  190. 190.
    Patterson TF. Approaches to therapy for invasive mycoses—the role of amphotericin b. Clin Infect Dis. 1998;26:339–40.PubMedCrossRefGoogle Scholar
  191. 191.
    Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am. 1995;9:1045–74.PubMedGoogle Scholar
  192. 192.
    Klont RR, Meis JF, Verweij PE. Critical assessment of issues in the diagnosis of invasive aspergillosis. Clin Microbiol Infect. 2001;7 Suppl 2:32–7.PubMedCrossRefGoogle Scholar
  193. 193.
    Haramati LB, Schulman LL, Austin JH. Lung nodules and masses after cardiac transplantation. Radiology. 1993;188:491–7.PubMedCrossRefGoogle Scholar
  194. 194.
    Hot A, Maunoury C, Poiree S, et al. Diagnostic contribution of positron emission tomography with [18f]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect. 2011;17:409–17.PubMedCrossRefGoogle Scholar
  195. 195.
    Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–60.PubMedCrossRefGoogle Scholar
  196. 196.
    Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Specie identification and antifungal susceptibility patterns of species belonging to aspergillus section nigri. Antimicrob Agents Chemother. 2009;53:4514–7.PubMedPubMedCentralCrossRefGoogle Scholar
  197. 197.
    Munoz P, Alcala L, Sanchez Conde M, et al. The isolation of Aspergillus fumigatus from respiratory tract specimens in heart transplant recipients is highly predictive of invasive aspergillosis. Transplantation. 2003;75:326–9.PubMedCrossRefGoogle Scholar
  198. 198.
    Yeo SF, Wong B. Current status of nonculture methods for diagnosis of invasive fungal infections. Clin Microbiol Rev. 2002;15:465–84.PubMedPubMedCentralCrossRefGoogle Scholar
  199. 199.
    Reichenberger F, Dickenmann M, Binet I, et al. Diagnostic yield of bronchoalveolar lavage following renal transplantation. Transpl Infect Dis. 2001;3:2–7.PubMedCrossRefGoogle Scholar
  200. 200.
    Husain S, Paterson DL, Studer SM, et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation. 2007;83:1330–6.PubMedCrossRefGoogle Scholar
  201. 201.
    Husain S, Raza K, Pilewski JM, et al. Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. Transplantation. 2009;87:1852–7.PubMedCrossRefGoogle Scholar
  202. 202.
    Paradowski LJ. Saprophytic fungal infections and lung transplantation—revisited. J Heart Lung Transplant. 1997;16:524–31.PubMedGoogle Scholar
  203. 203.
    Castelli C, Benazzo F, Minoli L, Marone P, Seghezzi R, Carlizzi CN. Aspergillus infection of the l3-l4 disc space in an immunosuppressed heart transplant patient. Spine. 1990;15:1369–73.PubMedCrossRefGoogle Scholar
  204. 204.
    Patterson TF. Fungal susceptibility testing: where are we now? Transpl Infect Dis. 2002;4:38–45.PubMedCrossRefGoogle Scholar
  205. 205.
    Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med. 2007;356:1481–3.PubMedCrossRefGoogle Scholar
  206. 206.
    Howard SJ, Webster I, Moore CB, et al. Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents. 2006;28:450–3.PubMedCrossRefGoogle Scholar
  207. 207.
    Bretagne S, Marmorat-Khuong A, Kuentz M, Latge JP, Bart-Delabesse E, Cordonnier C. Serum aspergillus galactomannan antigen testing by sandwich elisa: practical use in neutropenic patients. J Infect. 1997;35:7–15.PubMedCrossRefGoogle Scholar
  208. 208.
    Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001;97:1604–10.PubMedCrossRefGoogle Scholar
  209. 209.
    Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42:1417–27.PubMedCrossRefGoogle Scholar
  210. 210.
    Fortun J, Martin-Davila P, Alvarez ME, et al. Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients. Transplantation. 2001;71:145–9.PubMedCrossRefGoogle Scholar
  211. 211.
    Patterson JE, Zidouh A, Miniter P, Andriole VT, Patterson TF. Hospital epidemiologic surveillance for invasive aspergillosis: patient demographics and the utility of antigen detection. Infect Control Hosp Epidemiol. 1997;18:104–8.PubMedCrossRefGoogle Scholar
  212. 212.
    Patterson TF, Miniter P, Patterson JE, Rappeport JM, Andriole VT. Aspergillus antigen detection in the diagnosis of invasive aspergillosis. J Infect Dis. 1995;171:1553–8.PubMedCrossRefGoogle Scholar
  213. 213.
    Walsh EE. Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine. J Infect Dis. 1994;170:345–50.PubMedCrossRefGoogle Scholar
  214. 214.
    Yoshida M, Obayashi T, Iwama A, et al. Detection of plasma (1 → 3)-beta-d-glucan in patients with fusarium, trichosporon, saccharomyces and acremonium fungaemias. J Med Vet Mycol. 1997;35:371–4.PubMedCrossRefGoogle Scholar
  215. 215.
    Kawagishi N, Satoh K, Enomoto Y, et al. Risk factors and impact of beta-d glucan on invasive fungal infection for the living donor liver transplant recipients. Tohoku J Exp Med. 2006;209:207–15.PubMedCrossRefGoogle Scholar
  216. 216.
    Alexander BD. Diagnosis of fungal infection: new technologies for the mycology laboratory. Transpl Infect Dis. 2002;4:32–7.PubMedCrossRefGoogle Scholar
  217. 217.
    Mutschlechner W, Risslegger B, Willinger B, et al. Bronchoalveolar lavage fluid (1,3)beta-d-glucan for the diagnosis of invasive fungal infections in solid organ transplantation: a prospective multicenter study. Transplantation. 2015;99:e140–4.PubMedCrossRefGoogle Scholar
  218. 218.
    Hebart H, Löffler J, Meisner C, et al. Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis. 2000;181:1713–9.PubMedCrossRefGoogle Scholar
  219. 219.
    Walsh TJ, Francesconi A, Kasai M, Chanock SJ. PCR and single-strand conformational polymorphism for recognition of medically important opportunistic fungi. J Clin Microbiol. 1995;33:3216–20.PubMedPubMedCentralGoogle Scholar
  220. 220.
    Einsele H, Hebart H, Roller G, et al. Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol. 1997;35:1353–60.PubMedPubMedCentralGoogle Scholar
  221. 221.
    Van Burik JA, Myerson D, Schreckhise RW, Bowden RA. Panfungal PCR assay for detection of fungal infection in human blood specimens. J Clin Microbiol. 1998;36:1169–75.PubMedPubMedCentralGoogle Scholar
  222. 222.
    Badiee P, Kordbacheh P, Alborzi A, Malekhoseini SA. Invasive fungal infection in renal transplant recipients demonstrated by panfungal polymerase chain reaction. Exp Clin Transplant. 2007;5:624–9.PubMedGoogle Scholar
  223. 223.
    Boeckh M, Gallez-Hawkins GM, Myerson D, Zaia JA, Bowden RA. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation. 1997;64:108–13.PubMedCrossRefGoogle Scholar
  224. 224.
    Buess M, Cathomas G, Halter J, et al. Aspergillus-PCR in bronchoalveolar lavage for detection of invasive pulmonary aspergillosis in immunocompromised patients. BMC Infect Dis. 2012;12:237.PubMedPubMedCentralCrossRefGoogle Scholar
  225. 225.
    Guinea J, Padilla C, Escribano P, et al. Evaluation of mycassay aspergillus for diagnosis of invasive pulmonary aspergillosis in patients without hematological cancer. PLoS One. 2013;8, e61545.PubMedPubMedCentralCrossRefGoogle Scholar
  226. 226.
    Thornton CR. Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol. 2008;15:1095–105.PubMedPubMedCentralCrossRefGoogle Scholar
  227. 227.
    Miceli MH, Goggins MI, Chander P, et al. Performance of lateral flow device and galactomannan for the detection of aspergillus species in bronchoalveolar fluid of patients at risk for invasive pulmonary aspergillosis. Mycoses. 2015;58:368–74.PubMedCrossRefGoogle Scholar
  228. 228.
    Willinger B, Lackner M, Lass-Florl C, et al. Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis in solid organ transplant patients: a semiprospective multicenter study. Transplantation. 2014;98:898–902.PubMedCrossRefGoogle Scholar
  229. 229.
    Syhre M, Scotter JM, Chambers ST. Investigation into the production of 2-pentylfuran by Aspergillus fumigatus and other respiratory pathogens in vitro and human breath samples. Med Mycol. 2008;46:209–15.PubMedCrossRefGoogle Scholar
  230. 230.
    de Heer K, van der Schee MP, Zwinderman K, et al. Electronic nose technology for detection of invasive pulmonary aspergillosis in prolonged chemotherapy-induced neutropenia: a proof-of-principle study. J Clin Microbiol. 2013;51:1490–5.PubMedPubMedCentralCrossRefGoogle Scholar
  231. 231.
    Koo S, Thomas HR, Daniels SD, et al. A breath fungal secondary metabolite signature to diagnose invasive aspergillosis. Clin Infect Dis. 2014;59:1733–40.PubMedPubMedCentralCrossRefGoogle Scholar
  232. 232.
    Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563–71.PubMedCrossRefGoogle Scholar
  233. 233.
    Villacian JS, Paya CV. Prevention of infections in solid organ transplant recipients. Transpl Infect Dis. 1999;1:50–64.PubMedCrossRefGoogle Scholar
  234. 234.
    Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis. 2000;30:653–7.PubMedCrossRefGoogle Scholar
  235. 235.
    Collignon P, Hurley B, Mitchell D. Interaction of fluconazole with cyclosporin. Lancet. 1989;1:1262.PubMedCrossRefGoogle Scholar
  236. 236.
    Horton CM, Freeman CD, Nolan Jr PE, Copeland 3rd JG. Cyclosporine interactions with miconazole and other azole-antimycotics: a case report and review of the literature. J Heart Lung Transplant. 1992;11:1127–32.PubMedGoogle Scholar
  237. 237.
    Lopez-Gil JA. Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann Pharmacother. 1993;27:427–30.PubMedCrossRefGoogle Scholar
  238. 238.
    Keogh A, Spratt P, McCosker C, Macdonald P, Mundy J, Kaan A. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med. 1995;333:628–33.PubMedCrossRefGoogle Scholar
  239. 239.
    Wimberley SL, Haug 3rd MT, Shermock KM, et al. Enhanced cyclosporine-itraconazole interaction with cola in lung transplant recipients. Clin Transplant. 2001;15:116–22.PubMedCrossRefGoogle Scholar
  240. 240.
    Rolando N, Philpott-Howard J, Williams R. Bacterial and fungal infection in acute liver failure. Semin Liver Dis. 1996;16:389–402.PubMedCrossRefGoogle Scholar
  241. 241.
    Sobh MA, Hamdy AF, El Agroudy AE, et al. Coadministration of ketoconazole and cyclosporine for kidney transplant recipients: long-term follow-up and study of metabolic consequences. Am J Kidney Dis. 2001;37:510–7.PubMedCrossRefGoogle Scholar
  242. 242.
    Girmenia C, Luzi G, Monaco M, Martino P. Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J Clin Microbiol. 1998;36:1436–8.PubMedPubMedCentralGoogle Scholar
  243. 243.
    Rogers TR. Optimal use of existing and new antifungal drugs. Curr Opin Crit Care. 2001;7:238–41.PubMedCrossRefGoogle Scholar
  244. 244.
    Hilmarsdottir I, Thorsteinsson SB, Asmundsson P, Bodvarsson M, Arnadottir M. Cutaneous infection caused by Paecilomyces lilacinus in a renal transplant patient: treatment with voriconazole. Scand J Infect Dis. 2000;32:331–2.PubMedCrossRefGoogle Scholar
  245. 245.
    Munoz P, Marin M, Tornero P, Martin Rabadan P, Rodriguez-Creixems M, Bouza E. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis. 2000;31:1499–501.PubMedCrossRefGoogle Scholar
  246. 246.
    Al-Badriyeh D, Heng SC, Neoh CF, Slavin M, Stewart K, Kong DC. Pharmacoeconomics of voriconazole in the management of invasive fungal infections. Expert Rev Pharmacoecon Outcomes Res. 2010;10:623–36.PubMedCrossRefGoogle Scholar
  247. 247.
    Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin b for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408–15.PubMedCrossRefGoogle Scholar
  248. 248.
    Fortun J, Martin-Davila P, Sanchez MA, et al. Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur J Clin Microbiol Infect Dis. 2003;22:408–13.PubMedCrossRefGoogle Scholar
  249. 249.
    Veroux M, Corona D, Gagliano M, et al. Voriconazole in the treatment of invasive aspergillosis in kidney transplant recipients. Transplant Proc. 2007;39:1838–40.PubMedCrossRefGoogle Scholar
  250. 250.
    Schwartz S, Reisman A, Troke PF. The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis. Infection. 2011;39:201–10.PubMedCrossRefGoogle Scholar
  251. 251.
    Kramer M, Kramer MR, Blau H, Bishara J, Axer-Siegel R, Weinberger D. Intravitreal voriconazole for the treatment of endogenous aspergillus endophthalmitis. Ophthalmology. 2006;113:1184–6.PubMedCrossRefGoogle Scholar
  252. 252.
    Vila Arteaga J, Suriano MM, Stirbu O. Intravitreal voriconazole for the treatment of aspergillus chorioretinitis. Int Ophthalmol. 2011;31:341–4.PubMedCrossRefGoogle Scholar
  253. 253.
    Bruggemann RJ, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit. 2008;30:403–11.PubMedCrossRefGoogle Scholar
  254. 254.
    Gorski E, Esterly JS, Postelnick M, Trifilio S, Fotis M, Scheetz MH. Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections. Antimicrob Agents Chemother. 2011;55:184–9.PubMedCrossRefGoogle Scholar
  255. 255.
    Ayub A, Kenney CV, McKiernan FE. Multifocal nodular periostitis associated with prolonged voriconazole therapy in a lung transplant recipient. J Clin Rheumatol. 2011;17:73–5.PubMedCrossRefGoogle Scholar
  256. 256.
    Becce F, Malghem J, Lecouvet FE, Vande Berg BC, Omoumi P. Clinical images: voriconazole-induced periostitis deformans. Arthritis Rheum. 2012;64:3490.PubMedCrossRefGoogle Scholar
  257. 257.
    Hirota K, Yasoda A, Fujii T, Inagaki N. Voriconazole-induced periostitis in a patient with overlap syndromes. BMJ Case Rep. 2014;2014.Google Scholar
  258. 258.
    Tedja R, El-Sherief A, Olbrych T, Gordon S. Multifocal periostitis as a complication of chronic use of voriconazole in a lung transplant recipient. Transpl Infect Dis. 2013;15:424–9.PubMedCrossRefGoogle Scholar
  259. 259.
    Malani AN, Kerr L, Obear J, Singal B, Kauffman CA. Alopecia and nail changes associated with voriconazole therapy. Clin Infect Dis. 2014;59:e61–5.PubMedCrossRefGoogle Scholar
  260. 260.
    Vanacker A, Fabre G, Van Dorpe J, Peetermans WE, Maes B. Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient. Am J Transplant. 2008;8:877–80.PubMedCrossRefGoogle Scholar
  261. 261.
    Wojenski DJ, Bartoo GT, Merten JA, et al. Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients. Transpl Infect Dis. 2015;17:250–8.PubMedCrossRefGoogle Scholar
  262. 262.
    Neoh CF, Snell GI, Levvey B, et al. Lung transplant recipients receiving voriconazole and skin squamous cell carcinoma risk in Australia. Med J Aust. 2014;201:543–4.PubMedCrossRefGoogle Scholar
  263. 263.
    Wong JY, Kuzel P, Mullen J, et al. Cutaneous squamous cell carcinoma in two pediatric lung transplant patients on prolonged voriconazole treatment. Pediatr Transplant. 2014;18:E200–7.PubMedCrossRefGoogle Scholar
  264. 264.
    Williams K, Mansh M, Chin-Hong P, Singer J, Arron ST. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis. 2014;58:997–1002.PubMedCrossRefGoogle Scholar
  265. 265.
    Epaulard O, Villier C, Ravaud P, et al. A multistep voriconazole-related phototoxic pathway may lead to skin carcinoma: results from a French Nationwide Study. Clin Infect Dis. 2013;57:e182–8.PubMedCrossRefGoogle Scholar
  266. 266.
    Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26:1730–44.PubMedCrossRefGoogle Scholar
  267. 267.
    Leather H, Boyette RM, Tian L, Wingard JR. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin a in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2006;12:325–34.PubMedCrossRefGoogle Scholar
  268. 268.
    Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:552–9.PubMedCrossRefGoogle Scholar
  269. 269.
    Mathis AS, Shah NK, Friedman GS. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases. Transplant Proc. 2004;36:2708–9.PubMedCrossRefGoogle Scholar
  270. 270.
    Surowiec D, DePestel DD, Carver PL. Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management. Pharmacotherapy. 2008;28:719–29.PubMedCrossRefGoogle Scholar
  271. 271.
    Peksa GD, Schultz K, Fung HC. Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract. 2015;21:409–15.PubMedCrossRefGoogle Scholar
  272. 272.
    Ceberio I, Dai K, Devlin SM, et al. Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2015;50:438–43.PubMedPubMedCentralCrossRefGoogle Scholar
  273. 273.
    Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy. 2007;27:825–34.PubMedCrossRefGoogle Scholar
  274. 274.
    Linden PK, Coley K, Fontes P, Fung JJ, Kusne S. Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin b lipid complex and a historical cohort treated with conventional amphotericin b. Clin Infect Dis. 2003;37:17–25.PubMedCrossRefGoogle Scholar
  275. 275.
    Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation. 2006;81:320–6.PubMedCrossRefGoogle Scholar
  276. 276.
    Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin b as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (ambiload trial). Clin Infect Dis. 2007;44:1289–97.PubMedCrossRefGoogle Scholar
  277. 277.
    Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin b for suspected or proven aspergillosis. Clin Infect Dis. 1999;29:1402–7.PubMedCrossRefGoogle Scholar
  278. 278.
    Groetzner J, Kaczmarek I, Wittwer T, et al. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant. 2008;27:1–6.PubMedCrossRefGoogle Scholar
  279. 279.
    Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39:1563–71.PubMedCrossRefGoogle Scholar
  280. 280.
    Dockrell DH. Salvage therapy for invasive aspergillosis. J Antimicrob Chemother. 2008;61 Suppl 1:i41–4.PubMedCrossRefGoogle Scholar
  281. 281.
    Raad II, Zakhem AE, Helou GE, Jiang Y, Kontoyiannis DP, Hachem R. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies. Int J Antimicrob Agents. 2015;45:283–8.PubMedCrossRefGoogle Scholar
  282. 282.
    Sable CA, Nguyen BY, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis. 2002;4:25–30.PubMedCrossRefGoogle Scholar
  283. 283.
    Fortun J, Martin-Davila P, Montejo M, et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation. 2009;87:424–35.PubMedCrossRefGoogle Scholar
  284. 284.
    Denning DW, Marr KA, Lau WM, et al. Micafungin (fk463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006;53:337–49.PubMedCrossRefGoogle Scholar
  285. 285.
    Vazquez JA. Anidulafungin: a new echinocandin with a novel profile. Clin Ther. 2005;27:657–73.PubMedCrossRefGoogle Scholar
  286. 286.
    Dowell JA, Stogniew M, Krause D, Henkel T, Damle B. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J Clin Pharmacol. 2007;47:305–14.PubMedCrossRefGoogle Scholar
  287. 287.
    Herbrecht R, Nivoix Y, Fohrer C, Natarajan-Ame S, Letscher-Bru V. Management of systemic fungal infections: alternatives to itraconazole. J Antimicrob Chemother. 2005;56 Suppl 1:i39–48.PubMedCrossRefGoogle Scholar
  288. 288.
    Oshaughnessy EM, Peter J, Walsh TJ. In vitro additive and synergistic effect of two echinocandins, caspofungin and micafungin with voriconazole against Aspergillus fumigatus. In: 42nd ICAAC Meeting, San Diego. 2002; Abs M-856.Google Scholar
  289. 289.
    Manavathu EK, Ganesan LT, Cutright JL, Chandrasekar P. In vitro antifungal activity of voriconazole in two-drug combination with micafungin, caspofungin and amphotericin b. In: 42nd ICAAC Meeting, San Diego. 2002; Abs J-125.Google Scholar
  290. 290.
    Otrosky L, Matar M, Paetznick VL, Rodríguez JR, Chen E, Rex JH. In vitro synergy testing of anidulafungin and micafungin in combination with amphotericin b against aspergillus spp. and fusarium spp. In: 42nd ICAAC Meeting, San Diego. 2002; Abs M-1816.Google Scholar
  291. 291.
    Kontoyannis DA, Hachem R, Lewis RE, Rivero G, Kantarjian HM, Raad I. Efficacy and toxicity of the caspofungin/liposomal amphotericin b combination in documented or possible invasive aspergillosis in patients with hematologic malignancies. In: 42nd ICAAC Meeting, San Diego. 2002; Abs M 1820.Google Scholar
  292. 292.
    Menichetti F. Combining antifungal drugs: the future of antifungal therapy? In: 42nd ICAAC Meeting, San Diego. 2002; Abs 603.Google Scholar
  293. 293.
    Gentina T, de Botton S, Alfandari S, et al. Combination antifungals for treatment of pulmonary invasive aspergillosis refractory to amphotericin b in leukaemia patients. In: 42nd ICAAC Meeting, San Diego. 2002; Abs M-80.Google Scholar
  294. 294.
    Rex JH. Combination antifungal therapy. In: 42nd ICAAC Meeting, San Diego. 2002; M 632.Google Scholar
  295. 295.
    Petraitiene R, Petraitis V, Sarafandi A, et al. In: 42nd ICAAC Meeting, San Diego. 2002; Abs M-857.Google Scholar
  296. 296.
    Odds FC. State of the art minilecture: antifungal combinations. In: 42nd ICAAC Meeting, San Diego. 2002; Abs M-1812.Google Scholar
  297. 297.
    Thiebaut A, Antal D, Breysse MC, Pivot C. Refractory invasive fungal infections in patients with hematologic malignancies: combination of new antifungal agents (voriconazole or caspofungin) with amphotericin b. In: 42nd ICAAC Meeting, San Diego. 2002; Abs M-859.Google Scholar
  298. 298.
    Douglas CM, Abruzzo G, Bowman JC, et al. Caspofungin alone or in combination with itraconazole reduces fungal burden in a neutropenic guinea pig model of disseminated aspergillosis. In: 42nd ICAAC Meeting, San Diego. 2002; Abs M-1819.Google Scholar
  299. 299.
    Navjvar LK, Hernandez S, Bocanegra R, et al. Combination posaconazole and amphotericin b therapy of murine pulmonary acute aspergillosis. In: 42nd ICAAC Meeting, San Diego. 2002; M-1818.Google Scholar
  300. 300.
    Manavathu EK, Alangaden GJ, Chandrasekar P. Differential activity of triazoles in 2 drug combination with the echinocandin caspofungin against Aspergillus fumigatus. In: 42nd ICAAC Meeting, San Diego. 2002; Abs M-854.Google Scholar
  301. 301.
    Sole A, Morant P, Salavert M, Peman J, Morales P. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect. 2005;11:359–65.PubMedCrossRefGoogle Scholar
  302. 302.
    Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162:81–9.PubMedCrossRefGoogle Scholar
  303. 303.
    Munoz P, Singh N, Bouza E. Treatment of solid organ transplant patients with invasive fungal infections: should a combination of antifungal drugs be used? Curr Opin Infect Dis. 2006;19:365–70.PubMedCrossRefGoogle Scholar
  304. 304.
    Valerio M, Vena A, Bouza E, et al. How much European prescribing physicians know about invasive fungal infections management? BMC Infect Dis. 2015;15:80.PubMedPubMedCentralCrossRefGoogle Scholar
  305. 305.
    Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver transplant recipients. Am J Transplant. 2008;8:426–31.PubMedCrossRefGoogle Scholar
  306. 306.
    Munoz P, Rojas L, Valerio M, et al. National survey of antifungal management practices in solid organ transplantation (sot) in Spain. In: 49th ICAAC. 2009.Google Scholar
  307. 307.
    Anonimous. Voriconazole. The Medical Letter on Drugs and Therapeutics. 2002;44:63–6.Google Scholar
  308. 308.
    Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006;50:1570–2.PubMedPubMedCentralCrossRefGoogle Scholar
  309. 309.
    Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201–11.PubMedCrossRefGoogle Scholar
  310. 310.
    Capitano B, Potoski BA, Husain S, et al. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob Agents Chemother. 2006;50:1878–80.PubMedPubMedCentralCrossRefGoogle Scholar
  311. 311.
    Green M, Wald ER, Tzakis A, Todo S, Starzl TE. Aspergillosis of the CNS in a pediatric liver transplant recipient: case report and review. Rev Infect Dis. 1991;13:653–7.PubMedPubMedCentralCrossRefGoogle Scholar
  312. 312.
    Sandur S, Gordon SM, Mehta AC, Maurer JR. Native lung pneumonectomy for invasive pulmonary aspergillosis following lung transplantation: a case report. J Heart Lung Transplant. 1999;18:810–3.PubMedCrossRefGoogle Scholar
  313. 313.
    Gil-Lamaignere C, Winn RM, Simitsopoulou M, Maloukou A, Walsh TJ, Roilides E. Interferon gamma and granulocyte-macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against scedosporium spp.: comparison with aspergillus spp. Med Mycol. 2005;43:253–60.Google Scholar
  314. 314.
    Safdar A. Immunomodulation therapy for invasive aspergillosis: discussion on myeloid growth factors, recombinant cytokines, and antifungal drug immune modulation. Curr Fungal Infect Rep. 2010;4:1–7.PubMedCrossRefGoogle Scholar
  315. 315.
    Lehrnbecher T, Kalkum M, Champer J, Tramsen L, Schmidt S, Klingebiel T. Immunotherapy in invasive fungal infection—focus on invasive aspergillosis. Curr Pharm Des. 2013;19:3689–712.PubMedCrossRefGoogle Scholar
  316. 316.
    Roilides E, Blake C, Holmes A, Pizzo PA, Walsh TJ. Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J Med Vet Mycol. 1996;34:63–9.PubMedCrossRefGoogle Scholar
  317. 317.
    Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect. 1998;37:173–80.PubMedCrossRefGoogle Scholar
  318. 318.
    Sole A, Ussetti P. [Mold infections in lung transplants]. Rev Iberoam Micol. 2014;31:229–36.PubMedCrossRefGoogle Scholar
  319. 319.
    Paya CV. Prevention of fungal and hepatitis virus infections in liver transplantation. Clin Infect Dis. 2001;33:S47–52.PubMedCrossRefGoogle Scholar
  320. 320.
    Fisher NC, Singhal S, Miller SJ, Hastings JG, Mutimer DJ. Fungal infection and liposomal amphotericin b (ambisome) therapy in liver transplantation: a 2 year review. J Antimicrob Chemother. 1999;43:597–600.PubMedCrossRefGoogle Scholar
  321. 321.
    Reichenspurner H, Gamberg P, Nitschke M, et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin b prophylaxis. Transplant Proc. 1997;29:627–8.PubMedCrossRefGoogle Scholar
  322. 322.
    Ruffini E, Baldi S, Rapellino M, et al. Fungal infections in lung transplantation. Incidence, risk factors and prognostic significance. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:181–90.PubMedGoogle Scholar
  323. 323.
    Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin b prophylaxis for aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant. 2001;20:1274–81.PubMedCrossRefGoogle Scholar
  324. 324.
    Calvo V, Borro JM, Morales P, et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. Chest. 1999;115:1301–4.PubMedCrossRefGoogle Scholar
  325. 325.
    Sole A. Invasive fungal infections in lung transplantation: role of aerosolised amphotericin b. Int J Antimicrob Agents. 2008;32 Suppl 2:S161–5.PubMedCrossRefGoogle Scholar
  326. 326.
    Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin b concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation. 2003;75:1571–4.PubMedCrossRefGoogle Scholar
  327. 327.
    Hamacher J, Spiliopoulos A, Kurt AM, Nicod LP. Pre-emptive therapy with azoles in lung transplant patients. Geneva Lung Transplantation Group. Eur Respir J. 1999;13:180–6.PubMedCrossRefGoogle Scholar
  328. 328.
    Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl. 2006;12:850–8.PubMedCrossRefGoogle Scholar
  329. 329.
    Singhal S, Ellis RW, Jones SG, et al. Targeted prophylaxis with amphotericin b lipid complex in liver transplantation. Liver Transpl. 2000;6:588–95.PubMedCrossRefGoogle Scholar
  330. 330.
    Hellinger WC, Bonatti H, Yao JD, et al. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation. Liver Transpl. 2005;11:656–62.PubMedCrossRefGoogle Scholar
  331. 331.
    Reed A, Herndon JB, Ersoz N, et al. Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients. Liver Transpl. 2007;13:1743–50.PubMedCrossRefGoogle Scholar
  332. 332.
    Singh N, Mieles L, Yu VL, Gayowski T. Invasive aspergillosis in liver transplant recipients: association with candidemia and consumption coagulopathy and failure of prophylaxis with low-dose amphotericin b. Clin Infect Dis. 1993;17:906–8.PubMedCrossRefGoogle Scholar
  333. 333.
    Aguado JM, Varo E, Usetti P, et al. Safety of anidulafungin in solid organ transplant recipients. Liver Transpl. 2012;18:680–5.PubMedCrossRefGoogle Scholar
  334. 334.
    Saliba F, Pascher A, Cointault O, et al. Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients. Clin Infect Dis. 2015;60:997–1006.PubMedGoogle Scholar
  335. 335.
    Winston DJ, Limaye AP, Pelletier S, et al. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transplant. 2014;14:2758–64.PubMedCrossRefGoogle Scholar
  336. 336.
    Soave R. Prophylaxis strategies for solid-organ transplantation. Clin Infect Dis. 2001;33:S26–31.PubMedCrossRefGoogle Scholar
  337. 337.
    Snydman DR. Posttransplant microbiological surveillance. Clin Infect Dis. 2001;33:S22–5.PubMedCrossRefGoogle Scholar
  338. 338.
    Speich R, van der Bij W. Epidemiology and management of infections after lung transplantation. Clin Infect Dis. 2001;33:S58–65.PubMedCrossRefGoogle Scholar
  339. 339.
    Colquhoun IW, Gascoigne AD, Gould K, Corris PA, Dark JH. Native pulmonary sepsis after single-lung transplantation. Transplantation. 1991;52:931–3.PubMedCrossRefGoogle Scholar
  340. 340.
    Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-aspergillus mold infections in transplant recipients, United States, 2001–2006. Emerg Infect Dis. 2011;17:1855–64.PubMedPubMedCentralCrossRefGoogle Scholar
  341. 341.
    Cuenca-Estrella M, Bernal-Martinez L, Isla G, Gomez-Lopez A, Alcazar-Fuoli L, Buitrago MJ. Incidence of zygomycosis in transplant recipients. Clin Microbiol Infect. 2009;15 Suppl 5:37–40.PubMedCrossRefGoogle Scholar
  342. 342.
    Bitar D, Van Cauteren D, Lanternier F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006. Emerg Infect Dis. 2009;15:1395–401.PubMedPubMedCentralCrossRefGoogle Scholar
  343. 343.
    Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–53.PubMedCrossRefGoogle Scholar
  344. 344.
    Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant. 2006;6:2365–74.PubMedCrossRefGoogle Scholar
  345. 345.
    Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica. 2013;98:492–504.PubMedPubMedCentralCrossRefGoogle Scholar
  346. 346.
    Studemeister AE, Kozak K, Garrity E, Venezio FR. Survival of a heart transplant recipient after pulmonary cavitary mucormycosis. J Heart Transplant. 1988;7:159–61.PubMedGoogle Scholar
  347. 347.
    Muhm M, Zuckermann A, Prokesch R, Pammer J, Hiesmayr M, Haider W. Early onset of pulmonary mucormycosis with pulmonary vein thrombosis in a heart transplant recipient. Transplantation. 1996;62:1185–7.PubMedCrossRefGoogle Scholar
  348. 348.
    Kfoury AG, Smith JC, Farhoud HH, et al. Adjuvant intrapleural amphotericin b therapy for pulmonary mucormycosis in a cardiac allograft recipient. Clin Transplant. 1997;11:608–12.PubMedGoogle Scholar
  349. 349.
    Tan HP, Razzouk A, Gundry SR, Bailey L. Pulmonary rhizopus rhizopodiformis cavitary abscess in a cardiac allograft recipient. J Cardiovasc Surg (Torino). 1999;40:223–6.Google Scholar
  350. 350.
    Jimenez C, Lumbreras C, Aguado JM, et al. Successful treatment of mucor infection after liver or pancreas-kidney transplantation. Transplantation. 2002;73:476–80.PubMedCrossRefGoogle Scholar
  351. 351.
    Naguib MT, Huycke MM, Pederson JA, Pennington LR, Burton ME, Greenfield RA. Apophysomyces elegans infection in a renal transplant recipient. Am J Kidney Dis. 1995;26:381–4.PubMedCrossRefGoogle Scholar
  352. 352.
    Walker SD, Clark RV, King CT, Humphries JE, Lytle LS, Butkus DE. Fatal disseminated Conidiobolus coronatus infection in a renal transplant patient. Am J Clin Pathol. 1992;98:559–64.PubMedCrossRefGoogle Scholar
  353. 353.
    Nimmo GR, Whiting RF, Strong RW. Disseminated mucormycosis due to Cunninghamella bertholletiae in a liver transplant recipient. Postgrad Med J. 1988;64:82–4.PubMedPubMedCentralCrossRefGoogle Scholar
  354. 354.
    Kolbeck PC, Makhoul RG, Bollinger RR, Sanfilippo F. Widely disseminated cunninghamella mucormycosis in an adult renal transplant patient: case report and review of the literature. Am J Clin Pathol. 1985;83:747–53.PubMedCrossRefGoogle Scholar
  355. 355.
    Khan ZU, Ahmad S, Brazda A, Chandy R. Mucor circinelloides as a cause of invasive maxillofacial zygomycosis: an emerging dimorphic pathogen with reduced susceptibility to posaconazole. J Clin Microbiol. 2009;47:1244–8.PubMedPubMedCentralCrossRefGoogle Scholar
  356. 356.
    Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother. 2007;51:2587–90.PubMedPubMedCentralCrossRefGoogle Scholar
  357. 357.
    Alanio A, Garcia-Hermoso D, Mercier-Delarue S, et al. Molecular identification of mucorales in human tissues: contribution of PCR electrospray-ionization mass spectrometry. Clin Microbiol Infect. 2015;21:594 e591–5.Google Scholar
  358. 358.
    Hamdy NA, Andrew SM, Shortland JR, et al. Fatal cardiac zygomycosis in a renal transplant patient treated with desferrioxamine. Nephrol Dial Transplant. 1989;4:911–3.PubMedCrossRefGoogle Scholar
  359. 359.
    Singh N, Gayowski T, Singh J, Yu VL. Invasive gastrointestinal zygomycosis in a liver transplant recipient: case report and review of zygomycosis in solid-organ transplant recipients. Clin Infect Dis. 1995;20:617–20.PubMedCrossRefGoogle Scholar
  360. 360.
    Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of aspergillus-active antifungal therapy: a case–control observational study of 27 recent cases. J Infect Dis. 2005;191:1350–60.PubMedCrossRefGoogle Scholar
  361. 361.
    Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis. 2004;39:584–7.PubMedCrossRefGoogle Scholar
  362. 362.
    Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39:743–6.PubMedCrossRefGoogle Scholar
  363. 363.
    Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis. 2005;40:770–1.PubMedCrossRefGoogle Scholar
  364. 364.
    Pagano L, Offidani M, Fianchi L, et al. Mucormycosis in hematologic patients. Haematologica. 2004;89:207–14.PubMedGoogle Scholar
  365. 365.
    Blankenship JR, Wormley FL, Boyce MK, et al. Calcineurin is essential for Candida albicans survival in serum and virulence. Eukaryot Cell. 2003;2:422–30.PubMedPubMedCentralCrossRefGoogle Scholar
  366. 366.
    Kontoyiannis DP, Lewis RE, Alexander BD, et al. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother. 2008;52:735–8.PubMedCrossRefGoogle Scholar
  367. 367.
    Steinbach WJ, Singh N, Miller JL, et al. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. Antimicrob Agents Chemother. 2004;48:4922–5.PubMedPubMedCentralCrossRefGoogle Scholar
  368. 368.
    Dannaoui E, Schwarz P, Lortholary O. In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. Antimicrob Agents Chemother. 2009;53:3549–51.PubMedPubMedCentralCrossRefGoogle Scholar
  369. 369.
    Lanternier F, Sun HY, Ribaud P, Singh N, Kontoyiannis DP, Lortholary O. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis. 2012;54:1629–36.PubMedCrossRefGoogle Scholar
  370. 370.
    Demirag A, Elkhammas EA, Henry ML, et al. Pulmonary rhizopus infection in a diabetic renal transplant recipient. Clin Transplant. 2000;14:8–10.PubMedCrossRefGoogle Scholar
  371. 371.
    Munckhof W, Jones R, Tosolini FA, Marzec A, Angus P, Grayson ML. Cure of rhizopus sinusitis in a liver transplant recipient with liposomal amphotericin b. Clin Infect Dis. 1993;16:183.PubMedCrossRefGoogle Scholar
  372. 372.
    Webb M, Dowdy L, Bundschu C, Nery J, Schiff E, Tzakis AG. Cerebral mucormycosis after liver transplantation: a case report. Clin Transplant. 1998;12:596–9.PubMedGoogle Scholar
  373. 373.
    Sun H-Y, Aguado JM, Bonatti H, et al. Pulmonary zygomycosis in solid organ transplant recipients in the current era. Am J Transplant. 2009;9:2166–71.PubMedCrossRefGoogle Scholar
  374. 374.
    Sun HY, Forrest G, Gupta KL, et al. Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients. Transplantation. 2010;90:85–92.PubMedCrossRefGoogle Scholar
  375. 375.
    Dummer JS, Hardy A, Poorsattar A, Ho M. Early infections in kidney, heart, and liver transplant recipients on cyclosporine. Transplantation. 1983;36:259–67.PubMedCrossRefGoogle Scholar
  376. 376.
    Hall JC, Brewer JH, Reed WA, Steinhaus DM, Watson KR. Cutaneous mucormycosis in a heart transplant patient. Cutis. 1988;42:183–6.PubMedGoogle Scholar
  377. 377.
    Woods SG, Elewski BE. Zosteriform zygomycosis. J Am Acad Dermatol. 1995;32:357–61.PubMedCrossRefGoogle Scholar
  378. 378.
    Adriaenssens K, Jorens PG, Meuleman L, Jeuris W, Lambert J. A black necrotic skin lesion in an immunocompromised patient. Diagnosis: cutaneous mucormycosis. Arch Dermatol. 2000;136:1165–70.PubMedCrossRefGoogle Scholar
  379. 379.
    Baraia J, Munoz P, Bernaldo de Quiros JC, Bouza E. Cutaneous mucormycosis in a heart transplant patient associated with a peripheral catheter. Eur J Clin Microbiol Infect Dis. 1995;14:813–5.Google Scholar
  380. 380.
    Knoop C, Antoine M, Vachiery JL, et al. Gastric perforation due to mucormycosis after heart-lung and heart transplantation. Transplantation. 1998;66:932–5.PubMedCrossRefGoogle Scholar
  381. 381.
    Vera A, Hubscher SG, McMaster P, Buckels JA. Invasive gastrointestinal zygomycosis in a liver transplant recipient: case report. Transplantation. 2002;73:145–7.PubMedCrossRefGoogle Scholar
  382. 382.
    Irtan S, Lamerain M, Lesage F, et al. Mucormycosis as a rare cause of severe gastrointestinal bleeding after multivisceral transplantation. Transpl Infect Dis. 2013;15:E235–8.PubMedCrossRefGoogle Scholar
  383. 383.
    Viscoli C, Dodi F, Pellicci E, et al. Staphylococcus aureus bacteraemia, absidia corymbifera infection and probable pulmonary aspergillosis in a recipient of orthotopic liver transplantation for end stage liver disease secondary to hepatitis c. J Infect. 1997;34:281–3.PubMedCrossRefGoogle Scholar
  384. 384.
    Marco del Pont J, De Cicco L, Gallo G, Llera J, De Santibanez E, D’Agostino D. Hepatic arterial thrombosis due to mucor species in a child following orthotopic liver transplantation. Transpl Infect Dis. 2000;2:33–5.Google Scholar
  385. 385.
    Ville S, Talarmin JP, Gaultier-Lintia A, et al. Disseminated mucormycosis with cerebral involvement owing to rhizopus microsporus in a kidney recipient treated with combined liposomal amphotericin b and posaconazole therapy. Exp Clin Transplant. 2016;14:96–9.PubMedGoogle Scholar
  386. 386.
    Lanternier F, Dannaoui E, Morizot G, et al. A global analysis of mucormycosis in France: the retrozygo study (2005–2007). Clin Infect Dis. 2012;54 Suppl 1:S35–43.PubMedCrossRefGoogle Scholar
  387. 387.
    Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118:1216–24.PubMedPubMedCentralCrossRefGoogle Scholar
  388. 388.
    Saegeman V, Maertens J, Meersseman W, Spriet I, Verbeken E, Lagrou K. Increasing incidence of mucormycosis in University Hospital, Belgium. Emerg Infect Dis. 2010;16:1456–8.PubMedPubMedCentralCrossRefGoogle Scholar
  389. 389.
    Sun HY, Singh N. Emerging importance of infections due to zygomycetes in organ transplant recipients. Int J Antimicrob Agents. 2008;32 Suppl 2:S115–8.PubMedCrossRefGoogle Scholar
  390. 390.
    Tobon AM, Arango M, Fernandez D, Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis. 2003;36:1488–91.PubMedCrossRefGoogle Scholar
  391. 391.
    Brugiere O, Dauriat G, Mal H, et al. Pulmonary mucormycosis (zygomycosis) in a lung transplant recipient: recovery after posaconazole therapy. Transplantation. 2005;80:1361–2.PubMedCrossRefGoogle Scholar
  392. 392.
    Alexander BD, Perfect JR, Daly JS, et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation. 2008;86:791–6.PubMedCrossRefGoogle Scholar
  393. 393.
    Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47:364–71.PubMedPubMedCentralCrossRefGoogle Scholar
  394. 394.
    Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards Jr J, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009;48:1743–51.PubMedPubMedCentralCrossRefGoogle Scholar
  395. 395.
    Guembe M, Guinea J, Pelaez T, Torres-Narbona M, Bouza E. Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. Antimicrob Agents Chemother. 2007;51:3457–8.PubMedPubMedCentralCrossRefGoogle Scholar
  396. 396.
    Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg. 1994;57:1044–50.PubMedCrossRefGoogle Scholar
  397. 397.
    McCarty TP, Baddley JW, Walsh TJ, et al. Phaeohyphomycosis in transplant recipients: results from The Transplant Associated Infection Surveillance Network (TRANSNET). Med Mycol. 2015;53:440–6.PubMedCrossRefGoogle Scholar
  398. 398.
    Schieffelin JS, Garcia-Diaz JB, Loss Jr GE, et al. Phaeohyphomycosis fungal infections in solid organ transplant recipients: clinical presentation, pathology, and treatment. Transpl Infect Dis. 2014;16:270–8.PubMedCrossRefGoogle Scholar
  399. 399.
    Lastoria C, Cascina A, Bini F, et al. Pulmonary cladophialophora boppii infection in a lung transplant recipient: case report and literature review. J Heart Lung Transplant. 2009;28:635–7.PubMedCrossRefGoogle Scholar
  400. 400.
    Chowdhary A, Guarro J, Randhawa HS, et al. A rare case of chromoblastomycosis in a renal transplant recipient caused by a non-sporulating species of rhytidhysteron. Med Mycol. 2008;46:163–6.PubMedCrossRefGoogle Scholar
  401. 401.
    Huprikar S, Shoham S. Emerging fungal infections in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:262–71.PubMedCrossRefGoogle Scholar
  402. 402.
    Jha V, Krishna VS, Chakrabarti A, et al. Subcutaneous phaeohyphomycosis in a renal transplant recipient: a case report and review of the literature. Am J Kidney Dis. 1996;28:137–9.PubMedCrossRefGoogle Scholar
  403. 403.
    McGinnis MR, Pasarell L. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin b, with consideration of phylogenetic implications. J Clin Microbiol. 1998;36:2353–5.PubMedPubMedCentralGoogle Scholar
  404. 404.
    Munoz P, Bouza E. [Fungal infections in patients undergoing solid organ transplantation]. Enferm Infecc Microbiol Clin. 1997;15:34–50.PubMedGoogle Scholar
  405. 405.
    Mullane K, Toor AA, Kalnicky C, Rodriguez T, Klein J, Stiff P. Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. Transpl Infect Dis. 2007;9:89–96.PubMedCrossRefGoogle Scholar
  406. 406.
    Young CN, Meyers AM. Opportunistic fungal infection by fusarium oxysporum in a renal transplant patient. Sabouraudia. 1979;17:219–23.PubMedCrossRefGoogle Scholar
  407. 407.
    Girardi M, Glusac EJ, Imaeda S. Subcutaneous fusarium foot abscess in a renal transplant patient. Cutis. 1999;63:267–70.PubMedGoogle Scholar
  408. 408.
    Sampathkumar P, Paya CV. Fusarium infection after solid-organ transplantation. Clin Infect Dis. 2001;32:1237–40.PubMedCrossRefGoogle Scholar
  409. 409.
    Arney KL, Tiernan R, Judson MA. Primary pulmonary involvement of fusarium solani in a lung transplant recipient. Chest. 1997;112:1128–30.PubMedCrossRefGoogle Scholar
  410. 410.
    Guinvarc’h A, Guilbert L, Marmorat-Khuong A, et al. Disseminated fusarium solani infection with endocarditis in a lung transplant recipient. Mycoses. 1998;41:59–61.PubMedCrossRefGoogle Scholar
  411. 411.
    Guarro J, Nucci M, Akiti T, Gene J, Barreiro MD, Goncalves RT. Fungemia due to fusarium sacchari in an immunosuppressed patient. J Clin Microbiol. 2000;38:419–21.PubMedPubMedCentralGoogle Scholar
  412. 412.
    Garbino J, Uckay I, Rohner P, Lew D, Van Delden C. Fusarium peritonitis concomitant to kidney transplantation successfully managed with voriconazole: case report and review of the literature. Transpl Int. 2005;18:613–8.PubMedCrossRefGoogle Scholar
  413. 413.
    Lodato F, Tame MR, Montagnani M, et al. Systemic fungemia and hepatic localizations of fusarium solani in a liver transplanted patient: an emerging fungal agent. Liver Transpl. 2006;12:1711–4.PubMedCrossRefGoogle Scholar
  414. 414.
    Halpern M, Balbi E, Carius L, et al. Cellulitis and nodular skin lesions due to fusarium spp. in liver transplant: case report. Transplant Proc. 2010;42:599–600.PubMedCrossRefGoogle Scholar
  415. 415.
    Banerji JS, Singh JC. Cutaneous fusarium infection in a renal transplant recipient: a case report. J Med Case Rep. 2011;5:205.PubMedPubMedCentralCrossRefGoogle Scholar
  416. 416.
    Dahlan R, Patel A, Haider S. Successful use of posaconazole to treat invasive cutaneous fungal infection in a liver transplant patient on sirolimus. Can J Infect Dis Med Microbiol. 2012;23:e44–7.PubMedPubMedCentralGoogle Scholar
  417. 417.
    Keskar VS, Wanjare S, Jamale TE, et al. Subcutaneous hyalohyphomycosis caused by fusarium in a kidney transplant recipient. Ren Fail. 2014;36:1129–32.PubMedCrossRefGoogle Scholar
  418. 418.
    Harris LF, Dan BM, Lefkowitz Jr LB, Alford RH. Paecilomyces cellulitis in a renal transplant patient: successful treatment with intravenous miconazole. South Med J. 1979;72:897–8.PubMedCrossRefGoogle Scholar
  419. 419.
    Castro LG, Salebian A, Sotto MN. Hyalohyphomycosis by Paecilomyces lilacinus in a renal transplant patient and a review of human paecilomyces species infections. J Med Vet Mycol. 1990;28:15–26.PubMedCrossRefGoogle Scholar
  420. 420.
    Clark NM. Paecilomyces lilacinus infection in a heart transplant recipient and successful treatment with terbinafine. Clin Infect Dis. 1999;28:1169–70.PubMedCrossRefGoogle Scholar
  421. 421.
    Blackwell V, Ahmed K, O’Docherty C, Hay RJ. Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus in a renal transplant patient. Br J Dermatol. 2000;143:873–5.PubMedCrossRefGoogle Scholar
  422. 422.
    Das A, MacLaughlin EF, Ross LA, et al. Paecilomyces variotii in a pediatric patient with lung transplantation. Pediatr Transplant. 2000;4:328–32.PubMedCrossRefGoogle Scholar
  423. 423.
    Herranz P, Pizarro A, Garcia J, Gonzalez A, Casado M. [Inflammatory cutaneous nodules in an immunodepressed patient]. Enferm Infecc Microbiol Clin. 2000;18:521–3.Google Scholar
  424. 424.
    Naldi L, Lovati S, Farina C, Gotti E, Cainelli T. Paecilomyces marquandii cellulitis in a kidney transplant patient. Br J Dermatol. 2000;143:647–9.PubMedCrossRefGoogle Scholar
  425. 425.
    Ounissi M, Abderrahim E, Trabelsi S, et al. Hyalohyphomycosis caused by Paecilomyces lilacinus after kidney transplantation. Transplant Proc. 2009;41:2917–9.PubMedCrossRefGoogle Scholar
  426. 426.
    Kim JE, Sung H, Kim MN, et al. Synchronous infection with mycobacterium chelonae and paecilomyces in a heart transplant patient. Transpl Infect Dis. 2011;13:80–3.PubMedCrossRefGoogle Scholar
  427. 427.
    Berenguer J, Diaz-Mediavilla J, Urra D, Munoz P. Central nervous system infection caused by Pseudallescheria boydii: case report and review. Rev Infect Dis. 1989;11:890–6.PubMedCrossRefGoogle Scholar
  428. 428.
    Tadros TS, Workowski KA, Siegel RJ, Hunter S, Schwartz DA. Pathology of hyalohyphomycosis caused by Scedosporium apiospermum (Pseudallescheria boydii): an emerging mycosis. Hum Pathol. 1998;29:1266–72.PubMedCrossRefGoogle Scholar
  429. 429.
    Nesky MA, McDougal EC, Peacock Jr JE. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin Infect Dis. 2000;31:673–7.PubMedCrossRefGoogle Scholar
  430. 430.
    Tirado-Miranda R, Solera-Santos J, Brasero JC, Haro-Estarriol M, Cascales-Sanchez P, Igualada JB. Septic arthritis due to Scedosporium apiospermum: case report and review. J Infect. 2001;43:210–2.PubMedCrossRefGoogle Scholar
  431. 431.
    Berenguer J, Rodriguez-Tudela JL, Richard C, et al. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group. Medicine (Baltimore). 1997;76:256–65.Google Scholar
  432. 432.
    Idigoras P, Perez-Trallero E, Pineiro L, et al. Disseminated infection and colonization by Scedosporium prolificans: a review of 18 cases, 1990–1999. Clin Infect Dis. 2001;32:E158–65.PubMedCrossRefGoogle Scholar
  433. 433.
    Johnson LS, Shields RK, Clancy CJ. Epidemiology, clinical manifestations, and outcomes of scedosporium infections among solid organ transplant recipients. Transpl Infect Dis. 2014;16:578–87.PubMedCrossRefGoogle Scholar
  434. 434.
    Castiglioni B, Sutton DA, Rinaldi MG, Fung J, Kusne S. Pseudallescheria boydii (anamorph Scedosporium apiospermum) infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore). 2002;81:333–48.CrossRefGoogle Scholar
  435. 435.
    Jabado N, Casanova JL, Haddad E, et al. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin Infect Dis. 1998;27:1437–41.PubMedCrossRefGoogle Scholar
  436. 436.
    Tamm M, Malouf M, Glanville A. Pulmonary scedosporium infection following lung transplantation. Transpl Infect Dis. 2001;3:189–94.PubMedCrossRefGoogle Scholar
  437. 437.
    Oliveira JS, Kerbauy FR, Colombo AL, et al. Fungal infections in marrow transplant recipients under antifungal prophylaxis with fluconazole. Braz J Med Biol Res. 2002;35:789–98.PubMedGoogle Scholar
  438. 438.
    Wedde M, Muller D, Tintelnot K, De Hoog GS, Stahl U. PCR-based identification of clinically relevant pseudallescheria/scedosporium strains. Med Mycol. 1998;36:61–7.PubMedCrossRefGoogle Scholar
  439. 439.
    Williamson EC, Speers D, Arthur IH, Harnett G, Ryan G, Inglis TJ. Molecular epidemiology of Scedosporium apiospermum infection determined by PCR amplification of ribosomal intergenic spacer sequences in patients with chronic lung disease. J Clin Microbiol. 2001;39:47–50.PubMedPubMedCentralCrossRefGoogle Scholar
  440. 440.
    Steinbach WJ, Schell WA, Miller JL, Perfect JR. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol. 2003;41:3981–5.PubMedPubMedCentralCrossRefGoogle Scholar
  441. 441.
    Leechawengwongs M, Milindankura S, Liengudom A, Chanakul K, Viranuvatti K, Clongsusuek P. Multiple Scedosporium apiospermum brain abscesses after near-drowning successfully treated with surgery and long-term voriconazole: a case report. Mycoses. 2007;50:512–6.PubMedCrossRefGoogle Scholar
  442. 442.
    Sahi H, Avery RK, Minai OA, et al. Scedosporium apiospermum (pseudoallescheria boydii) infection in lung transplant recipients. J Heart Lung Transplant. 2007;26:350–6.PubMedCrossRefGoogle Scholar
  443. 443.
    Martel J, Faisant M, Lebeau B, Pinel C, Feray C, Feuilhade M. [Subcutaneous mycosis due to scopulariopsis brevicaulis in an immunocompromised patient]. Ann Dermatol Venereol. 2001;128:130–3.Google Scholar
  444. 444.
    Sellier P, Monsuez JJ, Lacroix C, et al. Recurrent subcutaneous infection due to scopulariopsis brevicaulis in a liver transplant recipient. Clin Infect Dis. 2000;30:820–3.PubMedCrossRefGoogle Scholar
  445. 445.
    Coley KC, Crain JL. Miconazole-induced fatal dysrhythmia. Pharmacotherapy. 1997;17:379–82.PubMedGoogle Scholar
  446. 446.
    Patel R, Gustaferro CA, Krom RA, Wiesner RH, Roberts GD, Paya CV. Phaeohyphomycosis due to Scopulariopsis brumptii in a liver transplant recipient. Clin Infect Dis. 1994;19:198–200.PubMedCrossRefGoogle Scholar
  447. 447.
    Wuyts WA, Molzahn H, Maertens J, et al. Fatal scopulariopsis infection in a lung transplant recipient: a case report. J Heart Lung Transplant. 2005;24:2301–4.PubMedCrossRefGoogle Scholar
  448. 448.
    Miossec C, Morio F, Lepoivre T, et al. Fatal invasive infection with fungemia due to Microascus cirrosus after heart and lung transplantation in a patient with cystic fibrosis. J Clin Microbiol. 2011;49:2743–7.PubMedPubMedCentralCrossRefGoogle Scholar
  449. 449.
    Shaver CM, Castilho JL, Cohen DN, et al. Fatal scopulariopsis infection in a lung transplant recipient: lessons of organ procurement. Am J Transplant. 2014;14:2893–7.PubMedPubMedCentralCrossRefGoogle Scholar
  450. 450.
    Rakita RM, Lease ED, Edelman JD, Mulligan MS. Successful treatment of scopulariopsis infection in a lung transplant recipient. Am J Transplant. 2015;15:2010.PubMedCrossRefGoogle Scholar
  451. 451.
    Pastor FJ, Guarro J. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect. 2006;12:948–60.PubMedCrossRefGoogle Scholar
  452. 452.
    Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52:1743–50.PubMedPubMedCentralCrossRefGoogle Scholar
  453. 453.
    Safdar A, Papadopoulos EB, Young JW. Breakthrough Scedosporium apiospermum (Pseudallescheria boydii) brain abscess during therapy for invasive pulmonary aspergillosis following high-risk allogeneic hematopoietic stem cell transplantation. Scedosporiasis and recent advances in antifungal therapy. Transpl Infect Dis. 2002;4:212–7.PubMedCrossRefGoogle Scholar
  454. 454.
    Herbrecht R, Waller J, Dufour P, et al. [Rare opportunistic fungal diseases in patients with organ or bone marrow transplantation]. Agressologie. 1992;33:77–80.PubMedGoogle Scholar
  455. 455.
    Meletiadis J, Mouton JW, Meis JF, Verweij PE. Combination chemotherapy for the treatment of invasive infections by Scedosporium prolificans. Clin Microbiol Infect. 2000;6:336–7.PubMedCrossRefGoogle Scholar
  456. 456.
    Steiner UC, Trueb RM, Schad K, et al. Trichophyton rubrum-induced majocchi’s granuloma in a heart transplant recipient. A therapeutic challenge. J Dermatol Case Rep. 2012;6:70–2.PubMedPubMedCentralCrossRefGoogle Scholar
  457. 457.
    Romero FA, Deziel PJ, Razonable RR. Majocchi’s granuloma in solid organ transplant recipients. Transpl Infect Dis. 2011;13:424–32.PubMedCrossRefGoogle Scholar
  458. 458.
    Voisard JJ, Weill FX, Beylot-Barry M, Vergier B, Dromer C, Beylot C. Dermatophytic granuloma caused by microsporum canis in a heart-lung recipient. Dermatology. 1999;198:317–9.PubMedCrossRefGoogle Scholar
  459. 459.
    King D, Cheever LW, Hood A, Horn TD, Rinaldi MG, Merz WG. Primary invasive cutaneous microsporum canis infections in immunocompromised patients. J Clin Microbiol. 1996;34:460–2.PubMedPubMedCentralGoogle Scholar
  460. 460.
    Virgili A, Zampino MR. Relapsing tinea capitis by microsporum canis in an adult female renal transplant recipient. Nephron. 1998;80:61–2.PubMedCrossRefGoogle Scholar
  461. 461.
    Sentamil Selvi G, Kamalam A, Ajithados K, Janaki C, Thambiah AS. Clinical and mycological features of dermatophytosis in renal transplant recipients. Mycoses. 1999;42:75–8.PubMedCrossRefGoogle Scholar
  462. 462.
    Virgili A, Zampino MR, La Malfa V, Strumia R, Bedani PL. Prevalence of superficial dermatomycoses in 73 renal transplant recipients. Dermatology. 1999;199:31–4.PubMedCrossRefGoogle Scholar
  463. 463.
    Franco RC. Deep dermatophytosis in a post transplant recipient. Int J Dermatol. 2001;40:363–4.PubMedCrossRefGoogle Scholar
  464. 464.
    Berg JC, Hamacher KL, Roberts GD. Pseudomycetoma caused by microsporum canis in an immunosuppressed patient: a case report and review of the literature. J Cutan Pathol. 2007;34:431–4.PubMedCrossRefGoogle Scholar
  465. 465.
    Chen CH, Wen MC, Cheng CH, et al. Infectious alopecia in a dog breeder after renal transplantation. J Chin Med Assoc. 2008;71:477–80.PubMedCrossRefGoogle Scholar
  466. 466.
    Zhang YQ, Xu XG, Li FQ, Wei H, Chen HD, Li YH. Co-existence of cutaneous alternariosis and tinea corporis in a renal transplant recipient. Med Mycol. 2011;49:435–8.PubMedCrossRefGoogle Scholar
  467. 467.
    Trabelsi S, Aouinet A, Abderrahim E, Ben Abdallah T, Khedher A, Khaled S. First case of subcutaneous dermatomycoses in a Tunisian renal transplant patient. Tunis Med. 2012;90:196–9.PubMedGoogle Scholar
  468. 468.
    Tse KC, Yeung CK, Tang S, et al. Majocchi’s granuloma and posttransplant lymphoproliferative disease in a renal transplant recipient. Am J Kidney Dis. 2001;38, E38.PubMedCrossRefGoogle Scholar
  469. 469.
    Liao YH, Chu SH, Hsiao GH, Chou NK, Wang SS, Chiu HC. Majocchi’s granuloma caused by trichophyton tonsurans in a cardiac transplant recipient. Br J Dermatol. 1999;140:1194–6.PubMedCrossRefGoogle Scholar
  470. 470.
    Sequeira M, Burdick AE, Elgart GW, Berman B. New-onset majocchi’s granuloma in two kidney transplant recipients under tacrolimus treatment. J Am Acad Dermatol. 1998;38:486–8.PubMedCrossRefGoogle Scholar
  471. 471.
    Jensen P, Lehne G, Fauchald P, Simonsen S. Effect of oral terbinafine treatment on cyclosporin pharmacokinetics in organ transplant recipients with dermatophyte nail infection. Acta Derm Venereol. 1996;76:280–1.PubMedGoogle Scholar
  472. 472.
    Gilmour TK, Rytina E, O’Connell PB, Sterling JC. Cutaneous alternariosis in a cardiac transplant recipient. Australas J Dermatol. 2001;42:46–9.PubMedCrossRefGoogle Scholar
  473. 473.
    Farina C, Gotti E, Parma A, Naldi L, Goglio A. Pheohyphomycotic soft tissue disease caused by Alternaria alternata in a kidney transplant patient: a case report and literature review. Transplant Proc. 2007;39:1655–9.PubMedCrossRefGoogle Scholar
  474. 474.
    Calabro G, Nino M, Gallo L, Scalvenzi M. Cutaneous alternariosis in a kidney transplantation recipient: report of a case. J Dermatolog Treat. 2008;19:246–8.PubMedCrossRefGoogle Scholar
  475. 475.
    Luque P, Garcia-Gil FA, Larraga J, et al. Treatment of cutaneous infection by Alternaria alternata with voriconazole in a liver transplant patient. Transplant Proc. 2006;38:2514–5.PubMedCrossRefGoogle Scholar
  476. 476.
    Gerdsen R, Uerlich M, De Hoog GS, Bieber T, Horre R. Sporotrichoid phaeohyphomycosis due to Alternaria infectoria. Br J Dermatol. 2001;145:484–6.PubMedCrossRefGoogle Scholar
  477. 477.
    Halaby T, Boots H, Vermeulen A, et al. Phaeohyphomycosis caused by Alternaria infectoria in a renal transplant recipient. J Clin Microbiol. 2001;39:1952–5.PubMedPubMedCentralCrossRefGoogle Scholar
  478. 478.
    Gallelli B, Viviani M, Nebuloni M, et al. Skin infection due to alternaria species in kidney allograft recipients: report of a new case and review of the literature. J Nephrol. 2006;19:668–72.PubMedGoogle Scholar
  479. 479.
    Laumaille C, Le Gall F, Degeilh B, Gueho E, Huerre M. [Cutaneous Alternaria infectoria infection after liver transplantation]. Ann Pathol. 1998;18:192–4.Google Scholar
  480. 480.
    Romano C, Valenti L, Miracco C, et al. Two cases of cutaneous phaeohyphomycosis by Alternaria alternata and alternaria tenuissima. Mycopathologia. 1997;137:65–74.PubMedCrossRefGoogle Scholar
  481. 481.
    Bourlond A, Alexandre G. Dermal alternariasis in a kidney transplant recipient. Dermatologica. 1984;168:152–6.PubMedCrossRefGoogle Scholar
  482. 482.
    Repiso T, Martin N, Huguet P, et al. Cutaneous alternariosis in a liver transplant recipient. Clin Infect Dis. 1993;16:729–30.PubMedCrossRefGoogle Scholar
  483. 483.
    Tan HP, Wahlstrom HE, Zamora JU, Hassanein T. Aureobasidium pneumonia in a post liver transplant recipient: a case report. Hepatogastroenterology. 1997;44:1215–8.PubMedGoogle Scholar
  484. 484.
    Koshi G, Anandi V, Kurien M, Kirubakaran MG, Padhye AA, Ajello L. Nasal phaeohyphomycosis caused by Bipolaris hawaiiensis. J Med Vet Mycol. 1987;25:397–402.PubMedCrossRefGoogle Scholar
  485. 485.
    Anandi V, John TJ, Walter A, et al. Cerebral phaeohyphomycosis caused by Chaetomium globosum in a renal transplant recipient. J Clin Microbiol. 1989;27:2226–9.PubMedPubMedCentralGoogle Scholar
  486. 486.
    Keyser A, Schmid FX, Linde HJ, Merk J, Birnbaum DE. Disseminated Cladophialophora bantiana infection in a heart transplant recipient. J Heart Lung Transplant. 2002;21:503–5.PubMedCrossRefGoogle Scholar
  487. 487.
    Harrison DK, Moser S, Palmer CA. Central nervous system infections in transplant recipients by Cladophialophora bantiana. South Med J. 2008;101:292–6.PubMedCrossRefGoogle Scholar
  488. 488.
    Levin TP, Baty DE, Fekete T, Truant AL, Suh B. Cladophialophora bantiana brain abscess in a solid-organ transplant recipient: case report and review of the literature. J Clin Microbiol. 2004;42:4374–8.PubMedPubMedCentralCrossRefGoogle Scholar
  489. 489.
    Salama AD, Rogers T, Lord GM, Lechler RI, Mason PD. Multiple cladosporium brain abscesses in a renal transplant patient: aggressive management improves outcome. Transplantation. 1997;63:160–2.PubMedCrossRefGoogle Scholar
  490. 490.
    Jacyk WK, Du Bruyn JH, Holm N, Gryffenberg H, Karusseit VO. Cutaneous infection due to Cladophialophora bantiana in a patient receiving immunosuppressive therapy. Br J Dermatol. 1997;136:428–30.PubMedCrossRefGoogle Scholar
  491. 491.
    Dupont C, Duong TA, Mallet S, et al. Unusual presentation of chromoblastomycosis due to Cladophialophora carrionii in a renal and pancreas transplant recipient patient successfully treated with posaconazole and surgical excision. Transpl Infect Dis. 2010;12:180–3.PubMedCrossRefGoogle Scholar
  492. 492.
    Aldape KD, Fox HS, Roberts JP, Ascher NL, Lake JR, Rowley HA. Cladosporium trichoides cerebral phaeohyphomycosis in a liver transplant recipient. Report of a case. Am J Clin Pathol. 1991;95:499–502.PubMedCrossRefGoogle Scholar
  493. 493.
    Mancini MC, McGinnis MR. Dactylaria infection of a human being: pulmonary disease in a heart transplant recipient. J Heart Lung Transplant. 1992;11:827–30.PubMedGoogle Scholar
  494. 494.
    Malani PN, Bleicher JJ, Kauffman CA, Davenport DS. Disseminated Dactylaria constricta infection in a renal transplant recipient. Transpl Infect Dis. 2001;3:40–3.PubMedCrossRefGoogle Scholar
  495. 495.
    Kralovic SM, Rhodes JC. Phaeohyphomycosis caused by dactylaria (human dactylariosis): report of a case with review of the literature. J Infect. 1995;31:107–13.PubMedCrossRefGoogle Scholar
  496. 496.
    Vukmir RB, Kusne S, Linden P, et al. Successful therapy for cerebral phaeohyphomycosis due to Dactylaria gallopava in a liver transplant recipient. Clin Infect Dis. 1994;19:714–9.PubMedCrossRefGoogle Scholar
  497. 497.
    Mazur JE, Judson MA. A case report of a dactylaria fungal infection in a lung transplant patient. Chest. 2001;119:651–3.PubMedCrossRefGoogle Scholar
  498. 498.
    Sudduth EJ, Crumbley 3rd AJ, Farrar WE. Phaeohyphomycosis due to exophiala species: clinical spectrum of disease in humans. Clin Infect Dis. 1992;15:639–44.PubMedCrossRefGoogle Scholar
  499. 499.
    Agger WA, Andes D, Burgess JW. Exophiala jeanselmei infection in a heart transplant recipient successfully treated with oral terbinafine. Clin Infect Dis. 2004;38:e112–5.PubMedCrossRefGoogle Scholar
  500. 500.
    Sindhuphak W, MacDonald E, Head E, Hudson RD. Exophiala jeanselmei infection in a postrenal transplant patient. J Am Acad Dermatol. 1985;13:877–81.PubMedCrossRefGoogle Scholar
  501. 501.
    Hachisuka H, Matsumoto T, Kusuhara M, Nomura H, Nakano S, Sasai Y. Cutaneous phaeohyphomycosis caused by Exophiala jeanselmei after renal transplantation. Int J Dermatol. 1990;29:198–200.PubMedCrossRefGoogle Scholar
  502. 502.
    Sabbaga E, Tedesco-Marchesi LM, Lacaz Cda S, et al. [Subcutaneous phaeohyphomycose due to exophiala jeanselmir. Report of 3 cases in patients with a kidney transplant]. Rev Inst Med Trop Sao Paulo. 1994;36:175–83.Google Scholar
  503. 503.
    McCown HF, Sahn EE. Subcutaneous phaeohyphomycosis and nocardiosis in a kidney transplant patient. J Am Acad Dermatol. 1997;36:863–6.PubMedCrossRefGoogle Scholar
  504. 504.
    Sartoris KE, Baillie GM, Tiernan R, Rajagopalan PR. Phaeohyphomycosis from exphiala jeanselmei with concomitant nocardia asteroides infection in a renal transplant recipient: case report and review of the literature. Pharmacotherapy. 1999;19:995–1001.PubMedCrossRefGoogle Scholar
  505. 505.
    Mesa A, Henao J, Gil M, Durango G. Phaeohyphomycosis in kidney transplant patients. Clin Transplant. 1999;13:273–6.PubMedCrossRefGoogle Scholar
  506. 506.
    Castro LG, da Silva Lacaz C, Guarro J, et al. Phaeohyphomycotic cyst caused by colletotrichum crassipes. J Clin Microbiol. 2001;39:2321–4.PubMedCrossRefGoogle Scholar
  507. 507.
    Boisseau-Garsaud AM, Desbois N, Guillermin ML, Ossondo M, Gueho E, Cales-Quist D. Onychomycosis due to Exophiala jeanselmei. Dermatology. 2002;204:150–2.PubMedCrossRefGoogle Scholar
  508. 508.
    Lief MH, Caplivski D, Bottone EJ, Lerner S, Vidal C, Huprikar S. Exophiala jeanselmei infection in solid organ transplant recipients: report of two cases and review of the literature. Transpl Infect Dis. 2011;13:73–9.PubMedCrossRefGoogle Scholar
  509. 509.
    Xu X, Low DW, Palevsky HI, Elenitsas R. Subcutaneous phaeohyphomycotic cysts caused by Exophiala jeanselmei in a lung transplant patient. Dermatol Surg. 2001;27:343–6.PubMedGoogle Scholar
  510. 510.
    Chua JD, Gordon SM, Banbury J, Hall GS, Procop GW. Relapsing Exophiala jeanselmei phaeohyphomycosis in a lung-transplant patient. Transpl Infect Dis. 2001;3:235–8.PubMedCrossRefGoogle Scholar
  511. 511.
    Gold WL, Vellend H, Salit IE, et al. Successful treatment of systemic and local infections due to exophiala species. Clin Infect Dis. 1994;19:339–41.PubMedCrossRefGoogle Scholar
  512. 512.
    Ajello L, Georg LK, Steigbigel RT, Wang CJ. A case of phaeohyphomycosis caused by a new species of phialophora. Mycologia. 1974;66:490–8.PubMedCrossRefGoogle Scholar
  513. 513.
    Jenney A, Maslen M, Bergin P, Tang SK, Esmore D, Fuller A. Pulmonary infection due to Ochroconis gallopavum treated successfully after orthotopic heart transplantation. Clin Infect Dis. 1998;26:236–7.PubMedCrossRefGoogle Scholar
  514. 514.
    Wang TK, Chiu W, Chim S, Chan TM, Wong SS, Ho PL. Disseminated Ochroconis gallopavum infection in a renal transplant recipient: the first reported case and a review of the literature. Clin Nephrol. 2003;60:415–23.PubMedCrossRefGoogle Scholar
  515. 515.
    Brokalaki EI, Sommerwerck U, von Heinegg EH, Hillen U. Ochroconis gallopavum infection in a lung transplant recipient: report of a case. Transplant Proc. 2012;44:2778–80.PubMedCrossRefGoogle Scholar
  516. 516.
    King D, Pasarell L, Dixon DM, McGinnis MR, Merz WG. A phaeohyphomycotic cyst and peritonitis caused by phialemonium species and a reevaluation of its taxonomy. J Clin Microbiol. 1993;31:1804–10.PubMedPubMedCentralGoogle Scholar
  517. 517.
    Porto E, Lacaz SC, Sabbaga E, et al. [Phialophora bubakii. Isolation from a subcutaneous abscess in a kidney-transplant patient]. Rev Inst Med Trop Sao Paulo. 1979;21:106–9.Google Scholar
  518. 518.
    Gallis HA, Berman RA, Cate TR, Hamilton JD, Gunnells JC, Stickel DL. Fungal infection following renal transplantation. Arch Intern Med. 1975;135:1163–72.PubMedCrossRefGoogle Scholar
  519. 519.
    Fincher RM, Fisher JF, Padhye AA, Ajello L, Steele Jr JC. Subcutaneous phaeohyphomycotic abscess caused by Phialophora parasitica in a renal allograft recipient. J Med Vet Mycol. 1988;26:311–4.PubMedCrossRefGoogle Scholar
  520. 520.
    Dooley DP, Beckius ML, Jeffery BS, et al. Phaeohyphomycotic cutaneous disease caused by pleurophoma in a cardiac transplant patient. J Infect Dis. 1989;159:503–7.PubMedCrossRefGoogle Scholar
  521. 521.
    Farina C, Punithaligham E, Ruggenenti P, Goglio A. Phaeohyphomycotic soft tissue disease caused by Pleurophomopsis lignicola in a kidney transplant patient. J Med Microbiol. 1997;46:699–703.PubMedCrossRefGoogle Scholar
  522. 522.
    Rockett MS, Gentile SC, Zygmunt KH, Gudas CJ. Subcutaneous phaeohypomycosis caused by Scytalidium dimidiatum in the foot of an immunosuppressed host. J Foot Ankle Surg. 1996;35:350–4.PubMedCrossRefGoogle Scholar
  523. 523.
    Foulet F, Duvoux C, de Bievre C, Hezode C, Bretagne S. Cutaneous phaeohyphomycosis caused by Veronaea bothryosa in a liver transplant recipient successfully treated with itraconazole. Clin Infect Dis. 1999;29:689–90.PubMedCrossRefGoogle Scholar
  524. 524.
    Strabelli TM, Uip DE, Amato Neto V, et al. [Acremonium infection after heart transplant]. Rev Soc Bras Med Trop. 1990;23:233.Google Scholar
  525. 525.
    Uip DE, Amato Neto V, Varejao Strabelli TM, et al. [Fungal infections in 100 patients subjected to heart transplantation]. Arq Bras Cardiol. 1996;66:65–7.Google Scholar
  526. 526.
    Geyer AS, Fox LP, Husain S, Della-Latta P, Grossman ME. Acremonium mycetoma in a heart transplant recipient. J Am Acad Dermatol. 2006;55:1095–100.PubMedCrossRefGoogle Scholar
  527. 527.
    Miro O, Ferrando J, Lecha V, Campistol JM. [Subcutaneous abscesses caused by acremonium falciforme in a kidney transplant recipient]. Med Clin (Barc). 1994;102:316.Google Scholar
  528. 528.
    Miro O, Campistol JM, Ribe A, Nicolas JM, Nadal P. Pulmonary acremonium abscesses and gastrointestinal tuberculosis manifested as massive upper gastrointestinal bleeding. Nephrol Dial Transplant. 1995;10:1444–6.PubMedGoogle Scholar
  529. 529.
    Van Etta LL, Peterson LR, Gerding DN. Acremonium falciforme (cephalosporium falciforme) mycetoma in a renal transplant patient. Arch Dermatol. 1983;119:707–8.PubMedCrossRefGoogle Scholar
  530. 530.
    Ko CI, Hung CC, Chen MY, Hsueh PR, Hsiao CH, Wong JM. Endoscopic diagnosis of intestinal penicilliosis marneffei: report of three cases and review of the literature. Gastrointest Endosc. 1999;50:111–4.PubMedCrossRefGoogle Scholar
  531. 531.
    Hart J, Dyer JR, Clark BM, McLellan DG, Perera S, Ferrari P. Travel-related disseminated penicillium marneffei infection in a renal transplant patient. Transpl Infect Dis. 2012;14:434–9.PubMedCrossRefGoogle Scholar
  532. 532.
    Marques SA, Camargo RM, Summerbell RC, et al. Subcutaneous phaeohyphomycosis caused by phaeoacremonium parasiticum in a renal transplant patient. Med Mycol. 2006;44:671–6.PubMedCrossRefGoogle Scholar
  533. 533.
    Heath CH, Lendrum JL, Wetherall BL, Wesselingh SL, Gordon DL. Phaeoacremonium parasiticum infective endocarditis following liver transplantation. Clin Infect Dis. 1997;25:1251–2.PubMedCrossRefGoogle Scholar
  534. 534.
    Shah SK, Parto P, Lombard GA, et al. Probable phaeoacremonium parasiticum as a cause of cavitary native lung nodules after single lung transplantation. Transpl Infect Dis. 2013;15:E9–13.PubMedCrossRefGoogle Scholar
  535. 535.
    Guarro J, Antolin-Ayala MI, Gene J, Gutierrez-Calzada J, Nieves-Diez C, Ortoneda M. Fatal case of trichoderma harzianum infection in a renal transplant recipient. J Clin Microbiol. 1999;37:3751–5.PubMedPubMedCentralGoogle Scholar
  536. 536.
    Furukawa H, Kusne S, Sutton DA, et al. Acute invasive sinusitis due to trichoderma longibrachiatum in a liver and small bowel transplant recipient. Clin Infect Dis. 1998;26:487–9.PubMedCrossRefGoogle Scholar
  537. 537.
    Jacobs F, Byl B, Bourgeois N, et al. Trichoderma viride infection in a liver transplant recipient. Mycoses. 1992;35:301–3.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Patricia Muñoz
    • 1
    • 2
  • Maddalena Giannella
    • 3
  • Antonio Vena
    • 1
    • 2
  • Emilio Bouza
    • 1
    • 2
  1. 1.CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058)MadridSpain
  2. 2.Instituto de Investigación Sanitaria Gregorio Marañón (IISGM) Dr. Esquerdo, 46, 28007MadridSpain
  3. 3.Department of Clinical Microbiology and Infectious DiseasesHospital General Universitario Gregorio Marañón, Dr. EsquerdoMadridSpain

Personalised recommendations